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 The sensing of viral infection through pattern recognition receptors is necessary to 
trigger an immune response through the expression of interferons (IFNs) and cytokines.  
For RNA viruses, which replicate in the cytoplasm, the cytoplasmic RIG-I like receptors 
are responsible for this sensing.  The contributions of these receptors to sensing viruses of 
the Picornaviridae family were investigated. Using bone marrow derived macrophages 
from MDA-5 and RIG-I null mice we showed that encephalomyocarditis virus (EMCV) 
and coxsackievirus B3 (CVB3), picornaviruses of the cardiovirus and the enterovirus 
genus respectively, are sensed by both MDA-5 and RIG-I.  Sensing of these viruses in 
macrophages leads to the expression of type I IFN early after infection with IFNβ 
expression reduced in the absence of each sensor, and IFNα expression reduced in the 
absence of MDA-5. However, in macrophages EMCV and CVB3 do not grow and we 
find that the sensing of viruses differs in murine embryonic fibroblasts (MEFs) and HeLa 
cells in which there is efficient replication. In MEFs RIG-I was found to be essential for 
the expression of type I IFNs but contribute to increases in viral titers in response to 
CVB3 infections.  MDA-5 inhibited CVB3 replication but in an IFN independent 
manner.  In HeLa cells MDA-5 was found to have no effect on the sensing of EMCV but 
to be important for the sensing of poliovirus. However mutants of these viruses changed 
the involvement of MDA-5 in sensing infection, indicating picornaviruses can evade 
sensing through different pathways. 
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Chapter I: Introduction 
 
1. Picornaviruses 
The Picornaviridae family is comprised of small RNA viruses that cause a variety 
of diseases in mammals with a diverse range of host tropism, severity and pathology.  
Within the family there are twelve genera and twenty-eight species (184)(Table1).  Of 
importance to humans are the members of the Hepatovirus, Enterovirus, Kobuvirus, and 
Parechovirus genera, which contain viruses whose natural host is humans.  Hepatitis A 
virus of the Hepatovirus genus is the etiological agent of hepatitis A, an acute hepatitis. 
Rhinoviruses are species of the Enterovirus genus and are a major causative agent of the 
common cold.  Within the same genus the more serious human disease, paralytic 
poliomyelitis is caused by the poliovirus, a member of the enterovirus C species.  In 1948 
another enterovirus was found to cause paralysis in Coxsackie, NY and named 
coxsackievirus.  There are two groups of coxsackieviruses, A and B, which belong to the 
enterovirus A and enterovirus B species respectively.  Seneca valley virus, whose natural 
host is pigs, is a notable picornavirus due to its selective ability to infect and lyse tumor 
cells in humans and has been through phase I trials for clinical use (67). 
Two important animal viruses are also contained in the Picornaviridae family, 
encepohalomyocarditis virus (EMCV) and foot and mouth disease virus (FMDV), which 
belong to the Cardiovirus and Apthovirus genera respectively.  FMDV is a highly 
infectious virus that can cause persistent infections of cloven-hoofed ruminants.  
Although infections result in low mortality there is high degree of morbidity, which 




livestock.  EMCV infects a wide number of animal species to cause encephalitis and 
myocarditis, causing problems for both farm and zoo animals.  Both of these 
picornaviruses are distinct from the more common human viruses of the Enterovirus 
genus in their coding for an extra non-structural protein, leader protein, their containing 
of a tract of over 200 cytosines (polyC tract) in their 5’ non-coding region, and the nature 
of the IRES (Figure1).  The leader protein in FMDV is a protease that inhibits an antiviral 
response by cleavage of NF-κB, while in EMCV it lacks protease activity but interferes 
with an antiviral response by preventing IRF3 dimerization (41).  The function of the 
polyC tract is unclear but shortening has been shown to decrease virulence.  The use of a 
type II IRES by EMCV and FMDV rather than the type I IRES used by enteroviruses 
allows for infection of a broader tissue range (25).  
Accordingly differences in functional properties of picornavirus IRESs correlate 
with differences in the structural properties of IRESs.  The type I IRES used by 
enteroviruses contains six stem loop domains termed stem loops I-VI.  The type II IRES 
used by cardioviruses and aphthoviruses contains twelve stem loop domains referred to as 
stem loops A-L.  The nucleotide sequences between IRESs of the same type may vary 
considerably but the predicted secondary structures are highly conserved because theses 
structures are thought to be important in the formation of higher order structures through 
RNA-RNA and RNA-protein interactions, which differ between IRES types.  Proper 
higher order structures are necessary for the proper recognition of the IRES by 
translational machinery.  In the case of type I IRESs the 40S ribosomal subunit is 




IRESs facilitate 40S ribosomal binding at the or near the start site, requiring no scanning 







Table 1. Picornaviridae Family.  Listing of all genera with in the 
picornavirus family and the number of species with in each genus in 
parenthesis.  Species with notable animal and human pathogens are 
shown with examples of viral strain/types with in the species, host and 






Figure 1. Picornavirus genomes. (A) Full genome sequences for 
isolates of representative genera and species are shown to scale, 
colored according to coding features, and aligned relative to the junction 
of 1D/2A.  Missing 5’ terminal data (No seq) are estimated in each case 
as 100 bases. The 3’ polyA tail (40-100 bases) is not shown. (B) Key 
features of representative 5’ and 3’ UTRs are drawn to scale. Known 
RNA structure elements include terminal clover leafs (CL), terminal 
stems (S), type I psuedoknots (y), polyC tracts(C), oligo pyrimidine 
tracts (Y), spacer segments (SP), IRESs (type I, II, III or IV), ORF 
initiation codons (AUG), and ORF termination codons (circle with slash).  






All members of the Picornaviridae family are single stranded positive sense RNA 
viruses with genomes in the range of 7-8Kb.  They are non-enveloped viruses with an 
icosahedral capsid.  The binding of this capsid to its receptor begins the infectious cycle 
(Figure 2).  For poliovirus this receptor is human CD155, also known as poliovirus 
receptor (PVR).  Murine cells are permissive to poliovirus but not susceptible due to the 
insufficient homology between the murine and human CD155 preventing poliovirus entry 
into murine cells.  The human coxsackievirus can use both human and murine 
coxsackievirus and adenovirus receptor (CAR) to gain entry into a host cell.  The 
receptor for EMCV is not fully characterized.  Vascular adhesion molecule 1 (VCAM-1) 
has been shown to be a receptor for EMCV on murine endothelial cells (47) but it is 
known that EMCV can also infect cells which do not express VCAM-1 such as HeLa and 
K562 cells.  In these cell lines a 70kDa sialoglycoprotein was found to act as a receptor 





Figure 2. The infectious cycle of picornaviruses. (1) Virus binds to 
its receptor and (2) releases its RNA genome into the cytoplasm. (3) 
The 5’ VPg protein is removed and cellular ribosomes bind the IRES to 
(4) translate the viral polyprotein.  (5) The polyprotein is cleaved during 
and after synthesis to produce individual viral proteins (only the initial 
cleavage is depicted). (6) The nonstructural proteins encoded in the P2 
and P3 regions of the polyprotein aid in the replication of the viral 
genome on membrane vesicles. (7) A switch is made to identify RNA as 
a template for replication and not translation. (8) The (+) strand RNA is 
copied into (-) strand RNA using a VPg primer that remains on the 5’ 
end.  (9) The (-) strand RNA is used as a template to produce multiple 
(+) strand genomic RNA also using a VPg primer which remains on the 
5’ end. (10) Some of the newly synthesized (+) strand RNA is used as a 
template for translation.  (11) The P1 region of the polyprotein is 
cleaved to form the structural proteins that form the capsid which then 
(12) associate with (+) strand RNA to assemble progeny virus that is 





Once bound the viral capsid undergoes conformational changes to release the 
RNA genome into the cytoplasm.  Since the genome is a positive sense strand of RNA 
with a polyA tail, cellular ribosomes directly bind the internal ribosomal entry site (IRES) 
to initiate cap independent translation and produce the viral poly protein (Figure 3).  This 
protein is then cleaved into 7-8 mature and 3 functional precursor non-structural proteins 
as well as the 4 structural proteins that form the capsid.  The non-structural (2A, 2B, 2C, 
3A, 3B, 3C, 3D, 2BC, 3AB, 3CD, L) proteins play a role in altering the cell to evade 
immune responses and redirect the cellular machinery for the production of more viral 








Figure 3. Picornavirus proteins. Schematic of the proteins produced 
by picornaviruses.  A single polyprotein is translated off of genomic 
RNA.  2A and 3C of enteroviruses are both proteases, 2Apro and 
3Cpro, which cleave the polyprotein in cis to produce the P1, P2, and 
P3 fragments.  These are further processed by cleavage to produce the 
11-12 mature viral proteins as well as 3 precursors 2BC, 3AB, and 3CD; 
which have functions independent of their mature forms.  Functions of 
proteins are indicated.  “Pro” superscript indicates protease activity; 
“pol” super script indicates polymerase activity.  Pink proteins contribute 
to protein processing.  L protein is not present in all picornaviruses. 





The production of viral genomes occurs on the surface of membrane vesicles 
induced by viral activation of the autophagy pathway by the 3A and 2BC proteins (64, 
142, 149) and is performed by a viral RNA dependent RNA polymerase, 3Dpol.  The 
polymerase 3Dpol is recruited to the viral RNA by interactions with protein complexes 
that form on the viral RNA at structured RNA sites in the 5’non-coding region, 3’ non-
coding region and the internal cis-regulatory element (CRE).  At the CRE 3Dpol interacts 
with a short viral protein 20-24aa long, 3B, and uses adenosines within a loop region of 
the CRE structure as a template to link uracil nucleotides to a tyrosine residue of 3B.  
This viral 3B protein linked with uracil nucleotides then becomes a primer for the 
synthesis of negative sense strand viral RNA when bound to the positive strand polyA 
tail.  The final product of negative strand synthesis is a fully duplexed double stranded 
RNA consisting of a positive strand and negative strand RNA which can be detected by 






Figure 4. Intracellular forms of picornavirus RNA. Following cell 
entry and uncoating, the picornavirus genomic RNA is altered by the 
cleavage of VPg from its 5’ terminus by an unidentified host cellular 
enzyme.  Genomic picornavirus RNA molecules lacking VPg are the 
templates for translation.  These templates for translation also serve as 
templates for (-) strand RNA synthesis, which results in a duplex of 
template and newly synthesized product RNA termed RF. Negative-
strand RNA molecules act as template for positive-strand RNA 
synthesis in RI complexes.  The RI complexes have multiple (+) strand 
RNAs synthesized from a single (-) strand template, resulting in 
asymmetric levels of positive versus negative strand viral RNAs in the 
infected cell.  The (+) strand viral RNA molecules can serve as the 
templates for additional rounds of translation or (-) strand RNA 
synthesis, or are packaged into virions for subsequent infection of other 






This newly synthesized negative strand of RNA is never found free but is used as 
the template for the production of multiple positive strand RNA genomes.  During this 
process viral RNA is found as a replicative intermediate (RI) which consists of multiple 
strands of positive RNA partially duplexed to negative RNA (106, 127).  Similar to 
negative strand synthesis the synthesis of positive strand RNA is performed by 3Dpol.  
The uracil linked 3B protein is used as a primer resulting in positive sense viral genomes 
with the 3B linked to the 5’ end, also known as VPg (viral protein genome-linked).  This 
protein is not necessary for viral infection but is a remnant of replication and is cleaved 
when viral genomes are released into the cytoplasm at the beginning of infection 
resulting in viral RNA with a pUp 5’end that is translated and replicated (4, 44, 104).  
After viral genomes are produced viral capsid proteins are recruited to sites of replication 
by the viral 2C protein and RNA genomes are packaged to form progeny viruses (82, 
105, 155).  These newly formed infectious particles are then released by both non-lytic 
and lytic paths (25, 29, 30, 64, 133)(Figure 2). 
 
2. Viral immunity 
 Defense against viral infections is comprised of both innate and adaptive immune 
responses.  The adaptive response consists of lymphoid cells, such as B and T cells, that 
collectively harbor a large repertoire of antigen specific receptors, with each lymphocyte 
specifically recognizing one antigen.  Mice deficient in these cells have shown their 
general importance for the clearance of many viral infections and survival of the host.  
Without cytotoxic T-cells to eliminate virus-infected cells or B-cell to produce 




 The innate immune response is a non-specific first line of defense that serves to 
contain the initial infection, aid in tissue repair, alert the host of pathogen infection, and 
steer the nature of the immune response.  The cellular mediators of these functions are 
monocytes, dendritic cells, natural killer cells, and polymorphonuclear leukocytes (60).  
Of great importance to the function as well as activation of these cells are a group of 
small signaling molecules called cytokines.  Various cytokines are initially released by 
infected cells, influencing the response of cells of the innate and in turn the adaptive 
immune response.   
 
Interferons 
 A key group of cytokines in viral defense are interferons.  Interferon was first 
identified 1957 as a secreted factor against heat inactivated influenza that “interfered” 
with infections by untreated influenza (49).  By the 1970s it was determined that different 
cells could produce antigenically distinct species of interferon (42, 78).  Fibroblasts 
produced one type, “F interferon”, while Leukocytes produced two, a minor amount of  
“F interferon” but mainly “Le interferon” (42).  More interferons have since been 
discovered and classified into three types based on their structure, receptor usage and 
function. 
Type I interferons consist of the leukocyte and fibroblast interferons now known 
as IFNα and IFNβ respectively.  This group also contains IFNδ, IFNω, IFNε, IFNκ, and 
IFNτ.  The IFNα, IFNβ, and IFNε type are found in mice and in humans. In addition to 
these three IFNs, humans also encode for IFNω and IFNκ.  IFNδ and IFNτ are produced 




contains just one species with the exception of IFNα of which there are 13 species of 
IFNα in humans and 14 in mice.  All type I IFNs signal through a ubiquitously expressed 
heterodimeric receptor composed of the transmembrane proteins IFNAR1 and IFNAR2 
(16, 40, 116, 134, 154) (Figure 6).  Expression of these IFNs is dependent on kinases that 
activate specific transcription factors, which bind to positive regulatory domains (PRDs) 
within IFN promoters (Figure 5).  The kinases TBK1 and IKKε phosporylate IRF3 and 
IRF7.  This phosphorylation results in their dimerization, nuclear translocation and 
binding to PRDI and PRDIII.  IKK (IκB kinase) phosporylates the IκB protein, releasing 
NFκB to bind PRDII binding sites on the IFNβ promoter. The kinases p38 and JNK (c-
Jun N-terminal kinase) phosporylate ATF-2 and c-Jun. This results in their 
heterodimerization and binding to PRDIV with in the IFNβ promoter. The cooperative 
binding of these transcription factors leads to the expression of IFNβ.  The IFNα 
promoters have similar PRD like elements (PRD-LE), which bind various IRFs to 
promote their expression.  The differential expression and activation of various IRFs and 
other transcription factors such as NF-κB and ATF-2/c-Jun allow for differential 









Figure 5. Type I and Type III interferon expression. Sensing of viral 
infection leads to the activation of several transcription factors involved 
in inducing the expression of type I and type III interferons. Activation of 
IRFs (yellow/orange), NFkB (green), and AP1 (pink) leads to nuclear 
localization and the recognition of their binding sites (color coded) with 
in the promoters of different IFN genes.  IFNβ and IFNλ1 promoters can 
be activated by IRF3 homodimers while IFNa and IFNλ2/3 promoters 





Type II interferon consists of only IFNγ which signals through a different 
heterodimeric receptor consisting of IFNGR1 and IFNGR2 (Figure 6).  Unlike type I 
IFNs, IFNγ binds as a dimer and forms a complex that consists of two heterodimeric 
receptors.  IFNGR1 is ubiquitously expressed while IFNGR2 expression is tightly 
regulated.  This regulation controls the population IFNγ responsive cells, making IFNγ 
more of an immunomodulator than an antiviral cytokine.  The expression of IFNγ is also 
different from Type I IFNs since it requires the transcription factor NFAT (nuclear factor 
activated T-cells) in addition to NFκB and AP-1 and is therefore only expressed by T-
cells and NK cells.  Additionally expression of INFγ is not induced by direct 
viral infection of NK or T-cells but in response to the cytokines IL-12 and 
IL-18 produced by activated macrophages (27, 28). 
 Type III interferons were discovered in 2003 by two groups through sequence 
analysis of the human genome for cytokines and cytokine receptors similar to those for 
interferons and IL-10 (69, 136).  This family was found to consist of three proteins 
IFNλ1, IFNλ2 and IFNλ3 (also known as IL-29, IL-28A, and IL-28B respectively).  In 
mice the gene for IFNλ1 is a pseudogene while IFNλ2 and IFNλ3 proteins are expressed 
(74).  In general Type III interferons seem to be quite similar to Type I interferons; they 
are induced by the same triggers of viral infection and TLR stimulation, regulated by the 
same transcriptions factors (Figure 5) and create an antiviral state after signaling through 
their receptors (6, 108, 112).  A key difference between the type I and type III interferons 
are their receptor usage, the IFNλs signal through a heterodimeric receptor composed of 
IFN-λR1 (IL-28RA) and IL-10R2 (IL-10Rβ) (69).  In vivo studies have shown that the 





interferons a more distinct role in viral infection, protecting mainly infections of the 







Figure 6. Interferon signaling. Type I, II and III interferons are 
characterized by the use of different receptors complexes on the cell 
surface. Binding of the soluble IFN to receptor complexes activates 
kinases associated with the intracellular domains of the receptor chains. 
This leads to the phosphorylation and dimerization of cytoplasmic STAT 
proteins.  STAT1 homodimers bind GAS sequences and lead to the 
induction of IFNγ induced genes such as ip-10, mig and irf-1.  STAT1 
and STAT2 heterodimers along with IRF9 form  the transcription factor 
ISGF3 which binds ISRE sequences to induce the expression of the 






 Although the different IFNs signal through different receptors the end result of 
creating an antiviral state within a cell that interferes with viral replication is similar.  The 
intracellular domains of the heterodimeric receptors associate with Janus protein tyrosine 
kinases.  In the case of Type I and type III interferons it is the Jak1 and tyk2 kinases and 
for type II interferons the Jak1 and Jak2 kinases (Figure 6).  Upon ligand binding these 
kinases are activated and phosporylate signal transducers and activators of transcription 
(STAT) proteins, mainly STAT1 and STAT2.  Once phosporylated these proteins 
dimerize to form two transcriptional activators.  IFNα-activated factor (AAF), also 
known as IFNγ-activated factor (GAF), consists of a phosporylated STAT1 homodimer 
that translocates to the nucleus and binds IFNγ-activated sequences (GAS).  The second 
transcriptional activator formed is IFN stimulated gene factor 3 (ISGF3), which consists 
of a phosphorylated heterodimer of STAT1 and STAT2 and the interferon regulatory 
factor 9 (IRF9) which binds to interferon stimulated regulatory elements (ISREs).  
Activation of the type I and type III IFN pathways primarily result in the formation of 
ISGF3 while activation of the type II IFN path in the formation of GAF.  The GAS and 
ISRE sequences these transcription factors bind are contained with in the promoters of 
hundreds of interferon-stimulated genes (ISGs) which are expressed after IFN signaling 
(16, 23, 28, 45, 68, 146).  It is the expression of these ISGs which result in the antiviral 
state of cells produced by interferons as many of these ISGs encode for proteins with 
antiviral activities.  The viral sensors MDA-5 and RIG-I are an example of some ISGs 
induced by IFN (55, 56, 141). 




to picornavirus infections.  OAS works in conjunction with RNaseL by converting ATP 
into 2’-5’-oligoadenylates when activated by dsRNA.  These 2’-5’-oligoadenylates 
activate the latent nuclease RNaseL which then dimerizes and degrades RNA molecules 
(22).  It has been shown that OAS and RNase L expression is able to reduce replication of 
EMCV (17, 179).  Additionally mice deficient in RNaseL have an increased mortality 
(180).  
 
3. Viral sensing – Pattern recognition receptors 
In order for IFNs to be expressed, antiviral states mounted and the cellular 
immune system activated, the host must first realize that it has been infected with by a 
viral pathogen.  This recognition occurs through receptors within cells which recognize 
molecules characteristic of viruses – namely the unique genomes or genomic 
intermediates of viruses.  There are two well-known classes of receptors that sense 
infection of RNA viruses, the toll-like receptors (TLRs) and the RIG-I like receptors 
(RLRs).   
Recently a set of cytoplasmic helicases (DDX1, DDX21 and DDX36) related to 
RIG-I, but not with in the RLR family, has also been shown to cooperatively act in the 
sensing of RNA in myeloid dendritic cells (178). DDX1 was found to bind polyI:C 
through it’s helicase domain while DDX21 and DDX36 bound the adaptor molecule 
TRIF (TIR-domain-containing adaptor inducing IFNβ) through its TIR (Toll/Interleukin-
1 receptor) domain.  The RNA bound DDX1 was bridged to TRIF and DDX36 through 
interactions with DDX21.  This DDX1-DDX21-DDX36-TRIF complex was found to 




and IFNβ expression.  Knockdown of any of the helicases in this complex has been 
shown to reduce the levels of IFNβ expressed after infection with Influenza A and 
Reovirus in DCs, but further experiments need to be done to characterize other viruses 
and RNA structures this complex may sense in cells other than DCs.   
 
Toll Like Receptors 
There are currently thirteen mammalian TLRs, ten human TLRs and twelve 
murine TLRs.  TLR 1-9 are shared between humans and mice, TLR10 is expressed in 
humans but is a pseudogene in mice, and TLR 11-13 are only present in mice (2, 3, 61, 
76).  The ligands have been determined for all TLRs but the human TLR10, and the 
murine TLR12 and TLR13 (76).   
 The TLR family of proteins are type I transmembrane proteins which function as 
homo or heterodimers and can reside either on the plasma membrane or endosomal 
membranes (Figure 7B).  They contain an extracellular or endosomal domain comprised 
of leucine rich repeats which bind to pattern associated molecular patterns (PAMPs) and 
a cytoplasmic Toll/IL-1 receptor homology domain (TIR) which associates with adaptor 
proteins to transmit signals.  With the exception of TLR3 all TLRs associate with the 
adaptor protein MyD88 (Myeloid differentiation primary response gene 88) which signals 
through TRAF6 (TNF associated factor 6) to activate the transcription factors NFκB and 
AP-1 and initiate the production of inflammatory cytokines.  TLR3 uses the adaptor 
protein TRIF (TIR-domain-containing adaptor inducing IFNβ) which utilizes TRAF3 to 




Activation of IRFs is crucial for the expression of IFNs and an antiviral response.  
The TLRs involved in an antiviral response are TLR3, TLR4, TLR7/8 and TLR9 (Figure 
7A).  TLR3 recognizes dsRNA, TLR4 recognizes viral envelope proteins, TLR7/8 
recognizes ssRNA and TLR9 recognizes DNA with GpG motifs (164).  TLR4 activates 
IRFs through interactions with TRIF as well as MyD88, however TLR 7/8 and TLR9 
only signal through MyD88.  These TLRs have been found to activate IRFs through 
MyD88 dependent associations with TRAF6, IRAK1 (interleukin-1 receptor-associated 
kinase), and IRAK4, but how this MyD88-TRAF6-IRAK1-IRAK4- signaling differs 
from the MyD88-TRAF6-IRAK1-IRAK4 signaling of TLR1, TLR2, TLR5 and TLR6 
which do not result in IRF activation is unknown.  It has been proposed that the location 
of TLR7/8 and TLR9 within endosomes rather than the plasma membrane is involved in 




Figure 7. Toll like receptor signaling. (A) Toll like receptors and their 
ligands. The main TLRs involved in sensing viral pattern recognition 
molecules are TLR7and TLR8 which recognize viral ssRNA and TLR3 
which recognizes viral dsRNA. TLR 9 which detects viral DNA and TLR4 
which can detect viral envelope proteins (B) Schematic of TLR 
signaling.  TLR 3, 7/8 and 9 are found in the endosomes while other 
TLRs are localized on the plasma membrane.  Most TLRs use the 
adaptor protein MyD88 to activate the transcription factors NFkB, AP-1 
and IRFs through TRAF6.  TLR 3 uses the adaptor protein TRIF and 
TRAF3 to activate IRFs.  These TLRs  along with TLR 9 reside in the 




RIG-I Like Receptors 
 
The RLR family of receptors contains three members.  RIG-I and MDA-5 are the 
two full length members of the family that consist of two N-terminal CARD domains, a 
DExD/H Box RNA Helicase domain and a C terminal Domain CTD.  Lgp-2 is similar in 
structure to RIG-I except that it lacks the N-terminal CARD domains (171, 173) (Figure 
8A).  This domain transmits the signal of infection through homotypic interaction with 
the card domain on the adaptor protein IPS-1.  The Helicase domain is involved in the 
binding of RNA which results in conformational changes and ATP hydrolysis to allow 
for exposure of the CARD domains.  The CTD contains a basic loop that binds RNA in 
RIG-I and Lgp-2, but is clipped in MDA-5 to form an open flat surface that does not bind 
RNA (144) (Figure 8B).  The CTD of RIG-I and Lgp-2 have also been shown to have 
repressor functions which MDA-5 does not have.   
Expression of these genes are detectable by microarray in most healthy human 
tissues (137, 169).  Quantitative PCR studies have shown thelevels of expression to be 
comparable among most tissues to levels in the spleen in humans, while expression in 
mice is greatest in the kidney and spleen (75).  Although detectable, the basal levels of 
RLR message are low compared to GAPDH but can be induced upon stimulation with 





Figure 8. RIG-I like receptor structure. The RLR family consists of 
three members: RIG-I, MDA-5 and LGP-2.  (A) RIG-I and MDA-5 
contain a CARD domain, helicase domain and C terminal domain while 
LGP2 only contains the helicase and C terminal domain.  The C terminal 
domain of RIG-I and LGP-2 are also repressor domains (RD).  Amino 
acid identity of the CARD domains and helicase/C terminal domain are 
indicated. (B) NMR based structure of the C terminal domain of each 
RLR member with a schematic representation beneath.  RIG-I and LGP-
2 structures are shown bound to RNA while MDA-5 cannot bind RNA 
due to the flat open structure of the basic loop responsible for RNA 





 Immuno-precipitation and FRET studies have shown that signaling through these 
receptors results in a transmembrane dependent dimerization of IPS-1 allowing it to then 
signal through TBK1, FADD and RIP1 to lead to the activation of IRF3 and NF-κB to 
transcribe IFNs and other cytokines (9, 62, 79, 85, 93, 135, 146, 148, 168).  It has also 
been shown that IPS-1 localizes to peroxisomal membranes as well as mitochondrial 
membranes.  Signaling through peroxisomal IPS-1 can directly induce the early 







Figure 9. RIG-I like receptor signaling. Infection with different viruses 
produces different forms of RNA which are recognized by different 
RLRs.  RNA binding to RIG-I leads to conformational changes which 
result in RIG-I ubiquitnination and dimerization to allow signaling.  This 
is promoted by SUMOlaytion and inhibited by phosphorylation and 
ISGylation with ISG15.  MDA-5 also undergoes a conformational 
change upon RNA binding and is positively regulated by SUMOlaytion.  
Signaling can occur through the adaptor protein IPS-1 which resides on 
peroxisomes and mitochondria.  Signaling through peroxisomal IPS-1 
results in an early response that activates IRF1 and IRF3 which can 
directly induce the expression of ISGs.  Signaling through the 
mitochondrial IPS-1 leads to the activation of IRF3, IRF7 and NFkB 
which induce the expression of Type I IFN and cytokines that must then 
signal through their receptors to turn on ISG expression create a 






 RIG-I was the first RLR to be identified as a sensor through a functional screen 
for proteins that could induce IFN by dsRNA stimulation, using the dsRNA mimic pI:C 
(172).  Later studies over-expressing, knocking down or knocking out RIG-I expression 
have shown its importance in sensing viruses from the Paramyxoviridae, Rhabdoviridae, 
Orthomyxoviridae, Filoviridae, Arenaviridae, Bunyaviridae and Flaviviridae families 
(37, 46, 57, 59, 83, 84, 88, 122, 143, 171, 181) (Table 2).  The majority of these virus 
families contain negative single stranded RNA genomes which do not produce detectable 
amounts of dsRNA during replication (119, 163).  This observation lead to the discovery 
that RIG-I sensing is independent of viral replication and senses ssRNA with a 
5’triphosphate (119, 143, 145, 163).  Recent studies involving pull-downs of RIG-I from 
influenza infected cells and analysis of bound RNA indicate that panhandle structures 








Table 2. Virus sensed by RIG-I and MDA-5. Viruses within indicated 
families sensed by RIG-I, MDA-5 or both.  Nature of viral genomes 
within each family are indicated as (-) or (+) sense, single or double 
strand RNA, and segmented (S) or non-segmented (NS).  Citations for 






A more thorough study on RIG-I RNA interactions performed by Takahasi et. al. 
looked at the structural requirements of RNA and the ATPase and helicase requirements 
of RIG-I for binding and signaling.  This study showed that recombinant RIG-I could 
bind 5’triphosphate ssRNA and dsRNA with a blunt end, 5’ overhang or 3’ overhang and 
pI:C independent of ATP but not 5’monophosphate ssRNA.  ATPase activity was 
essential for unwinding which occurred with dsRNA with a blunt or 3’overhang ends 
(145). Helicase activity was negatively correlated with IRF activation (8).  IRF 
dimerization was found to occur only with dsRNA with at least one strand mono-
phosphorylated and ssRNA with a 5’ tri-phosphate.  Binding of these species of RNA 
was also found to induce ATPase activity (145).  Although a 5’triphosphate is necessary 
for ssRNA recognition it is not sufficient for the sensing of HCV genomes which also 
requires polyU/UC region in the 3’NTR of the HCV genome (130, 153).  Additionally 
even self RNA can also become a ligand for RIG-I upon RNase L cleavage which 







Figure 10. RIG-I like receptor ligands.  MDA-5 has been shown to 
induce IFNβ promoter activity upon stimulation with undigested polyI:C  
greater than 2Kb in length.  RIG-I stimulation occurs with shorter polyI:C 
ligands of less than 300bp in length.  RIG-I treatment with dsRNA with at 
lease one strand with a monophosphate, ssRNA with a 5’ triphosphate, 
RNase L cleaved RNA with a 5’ hydroxyl and 3’ monophosphate and the 
double stranded panhandle structure of ssRNA DI particles have also 





In addition to the ligand requirements of RIG-I conformational requirements for 
signaling have been elucidated.  Protease treatment of recombinant RIG-I in the presence 
of dsRNA or 5’ triphosphate ssRNA results in the formation of a protease resistant 
polypeptide of 30kDa and in the presence of pI:C a resistant polypeptide of 60kDa, 
indicating conformational changes upon ligand binding controlling signaling (131, 145).  
In vivo studies using native gel electrophoresis show the formation of a multimeric RIG-I 
complex upon infection and in vitro studies using gel filtration indicate stable dimer 
formation upon ligand binding (19, 131).  A recent crystal structure of the helicase and C-
terminal domain of RIG-I suggest that in the absence of RNA RIG-I is in an inactive state 
with interactions between the helicase domain, CTD and CARD domains preventing the 
availability the CARD domains to bind IPS.  Upon RNA binding the CARD domains are 
displaced and the helicase and CTD domains wrap around the RNA strand, extending the 






Figure 11. RIG-I activation. (A) Linear schematic of RIG-I domains.  
Helicase consists of helicase domain1 (HEL1), helicase domain 2 
(HEL2) and Helicase domain 2 insertion (HEL2i) followed by a pincer 
region (P) and the C terminal domain (CTD). (B) Crystal structure of 
boxed region in (A) bound to RNA. (C) Schematic of conformational 
changes during RIG-I activation.  RIG-I is in a closed inactive form with 
CARD domains buried in interactions with helicase domains.  Binding of 
RNA (pink circle) to helicase domains and CTD results in the exposure 
of CARD domains.  ATP hydrolysis occurs and RIG-I molecules 






 Post-translational modifications regulating RIG-I signaling have also been 
identified.  The K63 poly-ubiquitination of the CARD domains by TRIM25 was the first 
modification found to be necessary for RIG-I  to bind IPS-1 and initiate signaling (34).  
Further ubiqutination of the N-terminal domain and C-terminal domain by REUL and 
RIPLET/RNF135 respectively also stimulates RIG-I activity (35, 109, 111).  Addition of 
the small ubiquitin-like modifier 1 (SUMO-1) onto RIG-I has been shown to increase its 
ubiquitination, interactions with IPS-1 and signaling (94).  Phosphorylation of the CARD 
domains at S8 or T170 can block TRIM25 binding and ubiquitination, and inhibit RIG-I 
signaling (33, 103).  However, if direct ubiquitination of the CARD domains is prevented 
by mutation it has been shown that in a reconstituted in vitro system the CARD domains 
can also bind free K63 poly-ubiquitin chains to mediate signaling (176).  It has not been 
determined whether phosphorylation inhibits binding of free poly-ubiquitin chains to 
reduce signaling.  Conjugation of ISG15, a ubiquitin-like protein, to RIG-I has been 
shown to reduce the levels of IFNβ promoter activity after stimulation (63).  This 
ISGylation of RIG-I is thought to work as a negative feedback loop to regulate the 
amount of IFN produced after the initial sensing.  Additionally poly-ubiquitination of 
RIG-I by RNF125, an E3 ligase expressed upon IFNα or pI:C treatment leads to  
proteasomal degradation of RIG-I as another negative feed back loop controlling RIG-I 
sensing (7) (Figure 9).  Aside from posttranslational modification, RIG-I  signaling was 
shown to be positively regulated through  direct binding with ZAPS (Zinc Finger 
Activated Protein Short)  and DDX60. (43, 95). 
 A knockout mouse for RIG-I was created to study the in vivo role of RIG-I during 




12.5 and 14.0, with only a few mice reaching birth.  These mice all died with in 3 weeks 
of birth, highlighting a role for RIG-I aside from an antiviral response (57).  RIG-I was 
first identified as an induced gene after retinoic acid treatment of leukemia cells 
indicating a role in carcinogenesis, apoptosis, senescence and differentiation (81).  A 
second knockout mouse targeting another region of RIG-I resulted in viable and fertile 
mice but developed a colitis-like phenotype associated with an increase in effector and 
decrease in naïve T-cells (159).  This mouse also possessed an increase in granulocytes, 
showing a role for RIG-I as a negative regulator in the development and differentiation of 
T-cells and granulocytes (177).  Unexpectedly it was also shown that RIG-I plays a role 
in phagocytosis using this mouse since they were found to be more susceptible to E. coli 
infection and RIG-I-/- macrophages showed a significant reduction in the ability to 
phagocytose GFP-E. coli (66). 
 
MDA-5 
 MDA-5 was first identified as a gene that was up regulated in melanoma cells 
induced to terminal differentiation by IFNβ and appropriately named Melanoma 
Differentiation Associated protein -5 (52).  After the full-length human gene was cloned, 
over-expression experiments showed that it was able to suppress the growth of melanoma 
cells and contribute to apoptosis (55, 56).  Cloning of the murine MDA-5 showed its 
ability to increase the rate of apoptosis through a caspase cleavage between the card and 
helicase domains.  This cleavage of the full-length cytoplasmic protein allowed for the 
helicase domain to translocate into the nucleus and accelerate DNA fragmentation – a 




 Although MDA-5 was known to be induced by IFNβ its antiviral role was not 
known until searches for mammalian DExD/H helicases similar to RIG-I identified it 
along with LGP2 as a related protein (171) (Figure 8A).  MDA-5 was then shown to 
activate IFNβ reporters upon pI:C treatment through IPS interactions, similar to RIG-I 
(62, 72, 171). 
 MDA-5 signaling is generally similar to that of RIG-I.  It exists in an inhibited 
form under physiological conditions, but un-like RIG-I this inhibited form is controlled 
by interactions with dihydroxyacetone kinase (DAK) through its NTD (20).  Upon viral 
infection DAK disassociates with MDA-5.  Recent structural studies on MDA-5 support 
a model where anti-parallel MDA-5 dimers cooperatively bind to dsRNA through the 
helicase domain to form a filament of MDA-5 visible by EM (15, 115).  ATP hydrolysis 
is not necessary for binding but does promote dissociation and is inversely proportional 
to filament length, indicating a  possible mechanisms for the discrimination of dsRNA 
length in sensing (115).  This oligomerized MDA-5 can then bind to and promote IPS-1 
oligomerization and signaling (8, 62, 72).  Similar to RIG-I signaling, MDA-5 is 
positively regulated by SUMOlaytion and negatively regulated by RNF125 ubiquitination 
(7, 32).  
 
Viruses sensed by MDA-5 and/or RIG-I 
 Two groups made MDA-5 knockout mice in 129x1/SvJ and C57BL/6 
backgrounds to study the effects of this sensor during different viral infections (36, 59).  
Unlike RIG-I knockout mice these mice were viable and showed no defects in any 




development as RIG-I does (36).  IFNβ ELISAs of RIG-I-/- and MDA-5-/- murine 
embryonic fibroblasts (MEFs) infected with VSV, SeV, NDA, Influenza, JEV and 
EMCV showed that RIG-I was important for the sensing of all these viruses except for 
EMCV, which was sensed by MDA-5 (59).  Additionally MDA-5 deficient mice infected 
with EMCV were more susceptible to infection than WT mice leading to the belief that 
RIG-I and MDA-5 are responsible for sensing different families of viruses.  RIG-I senses 
viruses of the Rhabdoviridae, Paramyxoviridae, Orthomyxoviridae and Flavivridae 
families and MDA-5 senses the synthetic pI:C and members of the Picornaviridae 
family.  Additionally studies comparing Norovirus infections in MDA-5 and TLR3 
deficient mice show that a virus of the Caliciviridae family is sensed by MDA-5 (91).  
Although mouse hepatitis virus (MHV), a member of the Coronaviridae family, induces 
minimal amounts of type I IFN in most tissues in brain microglia cells from WT, RIG-I, 
TLR3 and MyD88 deficient mice, IFNβ expression is detectable but reduced in MDA-5-/- 
microglia cells indicating that MDA-5 senses Coronaviridae infections (128).  MHV and 
a human coronavirus were shown to induce more IFN when the 2’-O-methyltransferase 
was mutated leading to 5’cap structures lacking 2’-O-methylation.  These viruses were 
shown to be sensed well by MDA-5 (183).  Recently the retrovirus SIV was shown to 
produce dsRNA sensed by MDA-5 in brains (18).  
 Later studies infecting RIG-I-/- and MDA-/- MEFs showed that for the Flaviviridae 
Dengue Virus and West Nile Virus both RIG-I and MDA-5 are individually dispensable 
for ISG expression, showing that some flaviviruses are sensed by both MDA-5 and RIG-I 
(31, 83).  Over expression of MDA-5 can also potentiate the sensing of measles virus and 




families can be sensed by MDA-5 as well as RIG-I (14, 138).  However a study on the 
sensing of DI particles of Sendai virus shows that this sensing is done through MDA-5, 
making it unclear if MDA-5 is sensing of paramyxoviruses is of the replicative viruses or 
only the byproduct of infection, defective interfering particles (174) (Table 2).  
 The factors that determine if a virus is sensed by MDA-5, RIG-I or both has 
therefore become a topic of interest.  One of the main determinants of MDA-5 vs. RIG-I 
sensing elucidated so far is dsRNA length.  By treating pI:C with RNase III for varying 
amounts of time various lengths of dsRNA were produced.  When MDA-5-/-  MEFs were 
treated with these RNAs the relative induction of IFNβ produced decreased with 
increased time of RNase treatment, indicating that sensing through RIG-I increased as 
pI:C length decreased.  The inverse was seen in RIG-I-/- MEFs indicating that sensing 
through MDA-5 decreased as pI:C length decreased (58).  Additionally treatment of these 
MEFs with RNA isolated from mock or Reovirus infected cells showed that Reovirus 
was sensed by both RIG-I and MDA-5.  The Reovirus genome consists of three dsRNA 
segments of different lengths: S (1.2-1.4kbp) M (2.2-2.3kbp) and L (3.9kbp).  When 
MEFs were treated with purified RNA of each segment it was shown that sensing of the S 
segment was dependent on RIG-I, sensing of M mainly on RIG-I but also MDA-5 and 
sensing of L dependent on both equally (58).  However, immuno-precipitation of dsRNA 
from EMCV infected cells, which was shown to induce IFN through MDA-5, revealed a 
prominent dsRNA band of >11kbp  which was not able to stimulate IFNβ production, 
indicating that long dsRNA alone cannot be sensed by MDA-5.  Only the very high 
molecular weight complex containing dsRNA and ssRNA that would be stuck in the 




proposing that high molecular weight RNA complexes are necessary to stimulate 
signaling through MDA-5 (120).  While many different RNA structures have been 
identified for the activation of RIG-I, the only structural characteristic for RNA to 
activate MDA-5 is size, however, the size of picornavirus genomes is one of the smallest 
(Figure 10).   
 
LGP2 
The third member of the RLR family, LGP2, can bind RNA through its C 
terminal domain but lacks the CARD domains which facilitate the transmission of a 
signal through interactions with the CARD domain of the RLR adaptor protein IPS1 (51, 
65, 145).  Over expression of LGP2 was shown to reduce the expression of ISRE, NFκB 
and PRDI reporters by infection with SeV and NDV, while knockdown of LGP2 resulted 
in an increase of reporter activity (129, 171) leading to the belief that the absence of 
CARD domains gave LGP2 a role as a negative regulator of RIG-I and MDA-5 signaling.  
Studies have also shown that LGP2 has a greater affinity for RNA than RIG-I and the RD 
domain of Lpg2 can interact with that of RIG-I and disrupt its ability to dimerize, leading 
to possible mechanisms of LGP2 negative regulation of RLR signaling (80, 121, 131).  
However Lgp2 knockout mice have been made by two groups reporting that in vivo 
infections of Lgp2 deficient mice by the picornavirus EMCV results in an increased 
lethality and a decrease in cytokine production arguing a case where LGP2 acts a positive 
regulator of RLR signaling (132, 156).  Although data on the role of LGP2 in EMCV 




LGP2 as a negative or positive regulator of other RLR ligands such as VSV and pI:C 
which has yet to be clarified (132, 156). 
 
5. Viral sensing and picornaviruses 
 Initially a study by Kato et. al. showed that there was an increase in mortality in  
mice deficient in MDA-5, MyD88 and IFNAR when infected with EMCV but not in 
mice deficient in RIG-I and TLR3 (59).  In vitro experiments infecting both MEFs and 
BMDCs from RIG-I knockout mice at varying multiplicities of infection showed no 
decrease in IFNβ expression at a low MOI and only a slight decrease in IFNβ expression 
at a high MOI.  EMCV infections of MDA-5-/- MEFs and bone marrow derived dendritic 
cells (BMDC) showed a complete ablation of IFNβ expression at various MOIs while 
bone marrow derived macrophages (BMDM) and peritoneal macrophage infections show 
a significant decrease in IFNα, IL-6 and MCP-1 at higher MOIs which disappears at 
lower MOIs (36).  These data led to the conclusion that MDA-5 is the main sensor of 
picornaviruses. 
 However, later studies infecting TLR3 deficient mice with either a myocarditic 
variant of EMCV or a diabetes inducing variant (EMCV-D) showed an increase in 
mortality, disease and viral titers in TLR3-/- mice compared to wild type mice indicating a 
role for TLR3 as a sensor for picornavirus infections (39, 91).  Consistent with the role of 
a sensor the loss of  TLR3 resulted in an early decrease in IFN during EMCV-D 
infections, although this decrease was transient.  On the contrary, infections with the 
myocarditic EMCV resulted in a transient increase in IFNβ message in cardiac tissue.  




viral sensing and immune response.  One study has shown a lack of TLR3 involvement in 
EMCV infection but other studies have shown that with different viral strains and 
infection conditions TLR3 does play a crucial role in viral infection.  It is therefore 
reasonable to investigate whether RIG-I, which has been previously shown to not be 
involved in sensing EMCV, has a role in picornavirus infections. 
 Studies using a picornavirus from the Enterovirus genus, Coxsackievirus, 
highlight the importance of mouse strains during in vivo studies.  Using mice deficient in 
MDA-5 in either a C57BL/6 background or a 129x1/SvJ background, infections with 
CVB3 at 105 pfu/mouse showed mice in the B6 background lacking MDA-5 had a 
significantly greater mortality than their wild type counterparts.  Meanwhile mice in a 
129 background, even those lacking MDA-5, showed no mortality at all and no 
difference in health was noticed between the control and MDA-5-/- mice (48).  This 
makes it even more difficult to conclude that RIG-I does not play a role in the sensing of 
picornaviruses since the MDA-5-/- mice and RIG-I-/- mice were made in different murine 
backgrounds, whose effects could be masking the role of RIG-I. 
  Additionally in vivo studies on the model picornavirus poliovirus further 
exemplify the importance of background strain as well as underscore the importance of 
infection conditions.  Mice deficient in TLR3 and its adaptor protein TRIF both show 
increased lethality compared to wild type controls after intravenous infection with 
poliovirus ranging from 102 pfu to 104 pfu.  This correlates nicely with an increase in 
viral load and a decrease in IFNα, OAS and IRF-7 expression, indicating TLR3 as an 
important sensor for PV infections.  However intravenous infections of MDA-5 knockout 




counter parts, but only when infected with 104 pfu.  Interestingly MDA-5 knockout mice 
in a B6 background infected with the same amount of virus actually have a greater 
survival rate than their wild type controls whether infected intravenously or 
intracerebrally.  Increasing the infectious dose to 105 pfu intravenously in the B6 mice 
reversed the phenotype of a loss of MDA-5 resulting in an increase in survival to a 
decrease in survival (1). 
 The myriad of cell types involved in in vivo infections could be contributing to 
this variability in results.  Infection of mice with EMCV-D show an increase in lethality 
in both MDA-5-/- and TLR3-/- mice compared to a wild type control.  By reconstituting γ-
irradiated MDA-5-/- or WT mice with bone marrow from WT or MDA-5-/- mice 
respectively bone marrow chimeric mice were made.  Infection of WT mice reconstituted 
with MDA-5-/- bone marrow (MDA5-/-  WT) showed complete resistance to EMCV-D 
infections, while those containing WT bone marrow in an MDA-5-/- mouse (WT  
MDA-5-/-) were susceptible to infection, similar to MDA-5-/- mice.  This indicates that the 
role of MDA-5 in sensing is important in non-hematopoietic, γ-irradiation resistant 
compartments.  Meanwhile similar bone marrow chimeras made with TLR3-/- mice 
showed that TLR3 protects against infection through the hematopoietic compartment 
(92). 
 In natural infections virus first replicates at the site of infection before progeny 
virus are released into the bloodstream to have direct access to multiple tissues.  The 
difference in sensors used in various tissues therefore leads to questions regarding the 
interpretation of in vivo models where systemic infections are directly established 




of the immune response in vivo makes the relative importance of sensors in these studies 
difficult to interpret on their own.  
  From current studies we have come to know that MDA-5 plays a role in the 
sensing of EMCV (36, 59, 92), Theilers (54), Coxsackie (48, 158) and poliovirus (1).  
Additionally we know through in vivo work that TLRs are also involved in the sensing of 
EMCV (39, 92), CVB3 (102), and PV (1).  This has lead to the in vitro examination and 
confirmation for the role of MDA-5 and TLRs in the sensing of rhinoviruses (139, 152, 
161, 162).  However, little work has been done looking at the role of RIG-I in the sensing 
of picornaviruses.  Papon et. al. has shown that during infections with EMCV RIG-I is 
degraded by both the picornaviral 3C protease as well as caspases, which can inhibit 
IFNβ expression through RIG-I. (114)  Our lab has also shown that the cleavage of RIG-I 
by EMCV, as well as the picornaviruses poliovirus, rhinovirus 16 and echovirus (11).  
Additionally it has been shown that the 3C of enterovirus 71 can inhibit sensing through 
RIG-I in a cleavage independent manner (77). 
This would seem to argue that RIG-I is irrelevant in picornavirus infections due to 
their ability to inhibit signaling through RIG-I.  However, it has also been shown that a 
number of these picornaviruses are also able to inhibit sensing by MDA-5 and TLRs.  
Our lab has also shown that MDA-5 is cleaved upon infections with poliovirus, EMCV, 
and rhinovirus 1a (10).  Rhinovirus1a, Coxsackie and Hepatitis A infections have all been 
shown to result in the cleavage of IPS-1, the adaptor molecule for RLRs (24, 86, 102, 
170).  The picornaviral 3C protease of Coxsackie and Hepatitis A virus has also been 




picornaviruses to dampen signals through these pathways it has been shown in many 
cases that these pathways can still confer protection to picornavirus infections. 
We therefore set out to study the role of the cytoplasmic sensors RIG-I and MDA-
5 in vitro with various cell types and picornaviruses viruses to discern the role theses 
sensors play in sensing virus in these cells and their affect on viral replication.  Using 
mice that were deficient in RIG-I and MDA-5 we were able to look at the role of RIG-I 
and MDA-5 in EMCV and CVB3 infections as model picornaviruses of the cardiovirus 
and enterovirus genera capable of infecting murine cells.  We were able to investigate the 
differences of sensors in the immune cells such as macrophages and “resident tissue 
cells”, fibroblasts.  Additionally using human HeLa cells KD for MDA-5 we could study 




Chapter 2: Material and Methods 
 
Constructs and cell lines 
HeLa S3 and 293A cells were maintained in Dulbecco’s modified essential 
medium (DMEM; Invitrogen, Carlsbad, CA)  supplemented with 10% bovine calf serum 
(Hyclone, Logan, UH) and 1% penicillin-streptomycin solution (Invitrogen). Over 
expression of MDA-5 was achieved by transfection of C terminal flagged MDA-5 in 
pcDNA3 using FuGene6 (Roche, Indianapolis, IN) according to manufacture protocol.  
Knockdown cell lines were produced by infection with retrovirus expressing miR30 
based short hairpin RNAs (shRNAs) designed against target genes.  Short hairpin RNA 
sequence for MDA-5 (5’TGCTGTTGACAGTGAGCGCACTGACATAAG 
AATCAATAAATAGTGAAGCCACAGATGTATTTATTGATTCTTATGTCAGTTTG
CCTACTGCCTCGGA3’) and RIG-I (5’TGCTGTTGACAGTGAGCGCTCAGCTACA 
GGGAATGAGTAATAGTGAAGCCACAGATGTATTACTCATTCCCTGTAGCTGA
ATGCCTACTGCCTCGGA3’) targets the 3’untranslated region of  the cellular mRNA 
and will not affect the expression of exogenously expressed constructs.  The IPS-1 
shRNA sequence (5’TGCTGTTGACAGTGAGCGATACCACCTTGATGCCTGTGAA 
TAGTGAAGCCACAGATGTATTCACAGGCATCAAGGTGGTAGTGCCTACTGCC
TCGGA3’) targets exon 5 of IPS-1 which is shared among IPS-1 variant.  Short hairpin 
RNA targeted against Luciferase was used as a control and previously published (24) 
Retroviruses were constructed by co-transfection of psPAX2, pMD.G and pAPM 
containing the shRNA sequence in 293A. Two days after transfection supernatants were 
harvested and used to infect target HeLa cells for knockdown.  Infected HeLa cells were 




 MDA-5-/- and matched wild type MEFs in a 129x1/SvJ background were a gift 
from Marco Collona. Washington University.  IFNAR-/- MEFs were also obtained on a 
129x1/SvJ background as a gift from David Levy, New York University.  RIG-I-/- and 
their matched wild type controls in a mixed ICR/B6/129 background were a gift from 
Michael Gale, University of Washington.  MEFs were maintained in DMEM 
supplemented with 15% Fetal Bovine Serum (Atlanta Biologicals, Lawrenceville, GA), 
1mM sodium pyruvate (Invitrogen), 2mM L-glutamine (Invitrogen), 1% penicillin-
streptomycin, 0.1mM Non-essential amino acids (Invitrogen).  
 MDA-5-/- and wild type control mice in a 129x1/SvJ background were a gift from 
Paula Longhi, Rockefeller University.  RIG-I-/- and wild type control mice in a mixed 
ICR/B6/129 background were a gift from Michael Gale, University of Washington.  Bone 
marrow from mice was harvested and cultured in DMEM supplemented with 20% L-cell 
conditioned media, 10% Fetal Bovine Serum, and 1% penicillin/streptomycin for 5-10 
days for 6-8days.   
 
Viruses 
 T7 polymerase (Fermentas) In vitro transcribed full length viral genomes were 
produced from plasmids containing DNA copies of PV, poliovirus type 1 Mahoney 
(pT7M); PV-Y88L, a poliovirus mutant containing a mutation from a tyrosine to leucine 
at residue 88 of 2A (pT7M-2A-Y88L); EMCV (pEC4); EP4, a EMCV-PV chimeric virus 
containing the poliovirus 2A protein with in the EMCV genome at the P1/P2 junction 
(pEC4-EP4), or CVB3 (pSVCVB3) (38, 101, 125, 151).  Viral stocks were produced by 




chimeric EP4C4 virus was isolated from plaque-purified clones of EP4 selected for their 
ability to replicate well in IFNα pretreated cells.  
 
Infections 
 Infections were performed in 35mm dishes.  Cells were counted at the time of 
infection and viral stocks were diluted to for infections at the appropriate MOI in 
PBS+0.01%BSA. Two hundred microliters of diluted virus was used to infect each plate 
at 37oC for 45min with rocking.  Cells were then washed twice with PBS and overlaid 
with 1mL of appropriate media.  
 
qPCR 
 Total RNA was harvested using a RNeasy Kit (Qiagen, Valencia, CA) with 
DNase I treatment (Qiagen) according to manufacturer protocol.  Complementary DNA 
was generated using iScript cDNA synthesis kit (BioRad, Hercules, CA) using both 
random hexamer and polyT primers according to manufacturer protocol.  Complementary 
cDNA was diluted 1:10 and qPCR done on individual genes using Syber Green PCR 
Master Mix (Applied Biosystems, Foster City, CA) and appropriate primers found on 
Table 3.  Quantitative PCR was performed in triplicate using an ABI 7500 real time PCR 
machine.  Data was analyzed using the 2ΔΔCt method as previously described using β-actin 
as the calibrator gene for murine qPCR and GAPDH as the calibrator for human qPCR 














Western Blot Analysis 
Cells were lysed in RIPA buffer and protein concentrations determined using 
Quick Start Bradford Dye Reagent 1x (BioRad).  Equal amounts of protein were run on 
10% SDS polyacrylimide gel and transferred overnight onto nitrocelluose membranes 
(EMD Millipore, Billerica, MA) and blocked for an hour in PBST+5% nonfat dry milk.  
Membranes were probed overnight with primary unconjugated antibody diluted in 
blocking buffer and washed 5 times with PBST before probing with secondary HRP 
conjugated antibody.  Membranes were incubated with appropriate HRP conjugated 
antibodies for one hour and washed 5 times with PBST again.  Blots were developed 
using Amersham ECL plus (GE Life sciences, Piscataway, NJ).  Antibodies and dilutions 















 Total virus samples were harvested by collecting supernatants from infected cells 
and supernatant after three cycles of freezing and thawing followed by centrifugation at 
5000xg for 5 min.  All titrations were done on monolayers of HeLa cells in six well 
plates.  Ten fold serial dilutions were made of virus in PBS+0.001% BSA (sigma, St. 
Louis, MO) and 0.1mL of viral dilutions was added per well.  Plates were incubated at 
37oC for 45min with rocking and then overlay added.  For PV and CVB3 a single agar 
overlay of 0.8% Bacto-agar (sigma) DMEM, 5%BCS, 0.05%NaHCO3, was used.  For 
EMCV a two-overlay system was used.  Overlay 1 was an agar overlay with a final 
composition of DMEM, 0.8% noble agar, 1%BCS, 0.2% NaHCO3, 50mM MgCl2, 1% 
non-essential amino acids. Overlay 2 was a liquid overlay with a final composition of 
DMEM, 0.1%BSA, 40mM MgCl2, 0.2% glucose, 2mM sodium pyruvate, 4mM L-
glutamine, 4mM oxaloacetic acid (Sigma), and 0.2% NaHCO3.  PV, CVB3 and EMCV 
plaque assays were incubated for 48hrs at 37oC. Cells were then fixed with 10%TCA 




Chapter 3: Sensing of EMCV 
 
Knock down of MDA-5 does not affect sensing of EMCV in HeLa cells 
 All previous literature has shown that the picornavirus EMCV is sensed through 
MDA-5 (36, 59, 91).  Therefore our first step in investigating the sensing of 
picornaviruses was to create a HeLa cell stably knocked down for MDA-5 which would 
be susceptible and permissive to human picornaviruses and the pan-tropic EMCV.  Basal 
expression of MDA-5 was knocked down in one cell line to undetectable levels by 
western blot (Figure 12A).  Upon stimulation of MDA-5 expression by IFNα or pI:C pre-
treatment MDA-5 protein could be detected in the knockdown cell line, however 
expression was greatly reduced compared to a control cell line containing a miRNA 






Figure 12. Knockdown of MDA-5 in HeLa cells.  HeLa cells were 
infected with lentivirus targeted to knockdown MDA-5 expression and 
infected cells selected by puromyocin treatment.  (A) Indicated cells 
lines were mock treated or treated with 20ug/mL of polyI:C for 16 hrs 
and cell extracts were analyzed by western blot. (B) Indicated cell lines 
were mock treated or treated with 1000U/mL of IFNa for 16 hrs.  Cell 





We hypothesized that in the absence of MDA-5 type I IFN would not be 
expressed upon EMCV infection and at a low MOI, which allows for multiple rounds of 
replication, we would therefore see an increase in viral titers since EMCV is known to be 
sensitive to type I IFN (17, 101).  However, infection of control and MDA-5 knockdown 







Figure 13.Effect of MDA-5 knockdown on EMCV replication.  MDA-5 
and control knockdown cell lines were infected with EMCV at an MOI of 
0.1.  Samples were harvested at indicated time points and viral titers 
determined by plaque assay. Representative data from one experiment 





Because basal levels of MDA-5 are low, knockdown cell lines were pre-treated 
with 0, 10, or 100 Units/mL of IFNα to increase the difference of MDA-5 present at the 
time of infection between MDA-5 and control knockdown cell lines, therefore increasing 
the difference in viral replication at low a low MOI.  IFNα pretreatment resulted in a 
decrease in viral titers in both cell lines with an increase in concentration of IFNα with 
only a very slight increase in viral titers in the MDA-5 knockdown line compared to 
control (Figure 14).  To ensure that the expression of other ISGs induced by IFNα 
treatment, which caused the overall decrease in viral titers in both the control and MDA-5 
knockdown cell lines, were not masking the effects of MDA-5 on viral replication we 
also over expressed MDA-5 in both cell lines and looked for differences in viral titers 







Figure 14. Effects of IFNα  pretreatment on EMCV replication. 
Control and MDA-5 knockdown cell lines were treated with IFNa at 
indicated concentrations for 18 hours and then infected with EMCV at 
an MOI of 0.1.  At various points post infection total virus was harvested 
and titers determined by plaque assay. Representative data from one 





Figure 15. Effect of MDA-5 over expression on EMCV replication. 
Control and MDA-5 knockdown cell lines were stably transfected with a 
plasmid expressing MDA-5 or empty vector. (A) Lysates from 
transfected cells were harvested and western blot analysis performed 
against MDA-5 and GAPDH (loading control). (B) Cell lines were 
infected with EMCV at an MOI of 0.1 and total virus harvested at various 
time points post infection.  Titers were determined by plaque assay. 
Representative data from one experiment of two independent 





Quantitative PCR was performed to examine the expression of type I IFN and 
downstream ISGs after EMCV infection.  Only a slight decrease in IFNβ induction was 
seen in MDA-5 knockdown cell lines compared to control cells (Figure 16B).  The 
induction of IFNβ did indeed produce an antiviral state within the cells as expression of 
the ISGs RIG-I, OAS and PKR were increased after infection in both cell lines, however 
there was little to no difference in the amount of ISG expression between cell lines 
(Figure 16 B, C).  This lack of difference in an antiviral state between cell lines however 
is likely not the cause for the lack of difference in viral titers since the expression of both 
IFNβ and ISGs occurs late, nine to twenty four hours post infection.  Viral replication 
however peaks at 9 hours post infection, before the induction of IFN and ISGs (Figure 
16A).  Therefore the lack of difference in viral titers is more likely due to the lack of any 







Figure 16. Role of MDA-5 in inducing an antiviral state in HeLa 
cells infected with EMCV. MDA-5 and control knockdown cell lines 
were infected at an MOI=0.1 with EMCV.  At indicated times post 
infection (A) total virus was harvested and titers assayed by plaque 
assay. (B) Total RNA was harvested and gene expression determined 
by qPCR for (B) IFNβ (C) indicated ISGs.  Values were normalized to β-
actin levels and fold change calculated relative to mock (M) infected 
samples. Representative data from one experiment of two independent 
experiments.  Plaque assays performed in duplicate and qPCR 






RIG-I is important and MDA-5 is essential for sensing EMCV infection of macrophages  
To confirm that the lack of difference in EMCV titers in control and MDA-5 
knockdown HeLa cells was not due to an incomplete knockdown of MDA-5 expression 
or sensing through an alternative path we tested EMCV infection in cells knocked out for 
MDA-5 or RIG-I.  Bone marrow derived macrophages from MDA-5-/- mice in a 
129x1/SvJ background (36) and RIG-I -/- mice in a mixed ICR background (59) and 
matched wild type controls were infected with EMCV at a low MOI.  Type I IFN 
induction was observed in WT cells from both backgrounds after EMCV infection, 
however with different kinetics.  In a mixed background there was a strong and early 
induction of IFNβ, peaking at 3 hours post infection, while in a 129x1/SvJ background 
the induction was more gradual peaking at 6 hours post infection (Figure 18).  To 
investigate this, the basal level of sensors was examined by qPCR using plasmids 
encoding for murine MDA-5 and RIG-I as standards.  The levels of RIG-I and MDA-5 
expression are both higher in macrophages derived from mice of a mixed ICR 
background than those in the 129x1/SvJ background.  Within each background however 
the expression of RIG-I is greater than MDA-5, and the ablation of one of the sensors 
does not lead to a change in the expression of the other (Figure 17A).  In both 
backgrounds this difference between RIG-I and MDA-5 expression is the same with 







Figure 17.  Basal levels of RIG-I and MDA-5 expression in 
macrophages. Total RNA from uninfected bone marrow derived 
macrophages of different mice was harvested and copies of RIG-I and 
MDA-5 mRNA calculated from qPCR using a plasmid standard. (A)  
Copy numbers were normalized to β-Actin Ct values. (B) Ratio of 
relative RIG-I to MDA-5 expression was calculated.  n=5 biological 
replicates, qPCR performed in triplicate. Error bars show standard 





Comparing each sensor knockout to its matched wild type control, the absence of 
MDA-5 shows the loss of induction of IFNβ as well as IFNα is lost.  In the absence of 
RIG-I the induction of IFNβ is greatly reduced while the induction of IFNα is not, but is 
actually induced to a greater extent than in wild type cells (Figure 18 A and B).  Enzyme 
linked immunosorbent assays for IFNα confirm this difference in the expression of IFNα 
is seen at the protein level as well as the RNA level (Figure 18 C).  The effects of these 
differences in type I IFN expression on viral replication are unknown since growth curves 
show limited viral replication and only a decrease in infectious particles, which occurs at 
the same rate both RIG-I-/- macrophages and MDA-5-/- macrophages and their wild type 
controls (Figure 18 D).  This indicates that EMCV does not productively infect 
macrophages, and during these non-productive infections MDA-5 is crucial for IFNα and 
IFNβ expression.  RIG-I, although not essential, is important for a robust IFNβ response, 





Figure 18. Role of MDA-5 and RIG-I in the induction of type I IFN in 
macrophages infected with EMCV. Bone marrow from knockout MDA-
5 or RIG-I mice and their matched wild type controls were harvested 
and cultured in  LCM conditioned media and infected with  EMCV at an  
MOI=1. Total RNA was harvested at various times posit infection and 
expression of (A) IFNβ and (B) IFNα examined by qPCR. (C) 
Supernatants were used to measure IFNα protein levels by ELISA. (D) 
Viral titers during infection were determined by plaque assay. 
Representative data from one experiment of three independent 
experiments.  Plaque assays performed in duplicate and qPCR 






RIG-I and MDA-5 contribute similarly to sensing EMCV infection of MEFs  
The role of MDA-5 and RIG-I in the sensing of EMCV infection was examined in 
the context of productive replication in MEFs.  In this cell type EMCV was found to 
replicate well (Figure 19A).  Type I IFN was induced in response to infection with 
kinetics similar to those seen in HeLa cells.  Peak expression of type I IFNs was seen at 
24 hours post infection with significant levels only appearing at 9 hours post infection.  
This resulted in a late induction of expression of the ISG OAS.  The absence of both 
MDA-5 and RIG-I resulted in a marked decrease in the amounts of IFNβ, IFNα and OAS 
(Figure 19 B-D).  These decreases in antiviral response had no effect on viral replication 
since notable amounts of type I IFN in wild type cells were not produced until after the 
peak of viral replication.  However, the magnitude of the decrease in type I IFNs in the 
absence of MDA-5 and RIG-I indicate that both proteins are involved in the sensing of 






Figure 19. Role of MDA-5 and RIG-I in the induction of an antiviral 
state in MEFs infected with EMCV.  MDA-5 and RIG-I deficient MEFs 
and their matched wild type controls were infected with EMCV at an 
MOI=1.  At various times post infection total RNA and total virus was 
harvested. (A) Viral titers during infection were determined by plaque 
assay and (B) IFNβ (C) IFNa and (D) OAS expression determined by 
qPCR. Representative data from one experiment of three independent 
experiments.  Plaque assays performed in duplicate and qPCR 





Sensing of EMCV in MEFs in replication dependent 
 
Because the roles of MDA-5 and RIG-I in sensing EMCV infection were different 
in MEFs, where viral replication was robust, than in macrophages, where viral replication 
was very poor, the role of replication in viral sensing was examined in MEFs. MDA-5-/-, 
RIG-I-/- and matched WT control MEFs were treated with one pfu or UV inactivated pfu 
per cell.  Total virus was harvested from both conditions 24 hours post treatment and 
plaque assays were performed to ensure that no viral replication occurred in MEFs 
treated with UV inactivated virus.  Replicating virus was sensed in wild type, MDA-5-/- 
and RIG-I-/- MEFs to lead to the induction of IFNβ and IFNα 24 hours post treatment.  
However treatment with UV inactivated EMCV resulted in no notable induction of IFNβ 
or IFNα in either wild type, MDA-5-/- or RIG-I-/- cells indicating that sensing in MEFs is 






Figure 20. Role of EMCV replication on the induction of an MDA-5 
dependent antiviral state in MEFs. (A,B) MDA-5 and (C,D) RIG-I 
deficient MEFs and their matched WT controls were treated with EMCV 
or UV inactivated EMCV at concentration of 1pfu or UV inactivated pfu 
per cell. Total RNA was collected at 24hrs p.i. from mock (M) and 
EMCV (24C) treated cells as controls and at varying times post UV 
inactivated EMCV treatment and expression of (A,C) IFNβ and (B,D) 
IFNa determined by qPCR. Representative data from one experiment of 
two independent experiments, qCR performed in triplicate.  Error bars 





  In summary we have shown that EMCV is sensed by both MDA-5 and RIG-I in 
murine cells.  In murine macrophages, MDA-5 is essential for IFNβ and IFNα expression 
while RIG-I is important for maximal levels of IFNβ expression but not IFNα 
expression.  In MEFs Both MDA-5 and RIG-I are needed for a robust IFNβ and IFNα 
response.  This response in MEFs occurs late in infection, after the peak of viral growth 
and therefore does not affect viral titers.  In macrophages the expression of if type I IFNs 
occurs very early after infection, but does not have an effect on viral replication since 
replication in macrophages is poor to begin with.  In human HeLa cells EMCV replicates 
well similar to MEFs, but MDA-5 does not contribute greatly to the expression of IFNβ 




Chapter 4: Sensing of Coxsackievirus 
 
RIG-I is important and MDA-5 is essential for the sensing of CVB3 infection of 
macrophages 
 Most picornaviruses belong to the Enterovirus genus, yet most of the work done 
on sensing of picornaviruses has been done using EMCV, one of two viruses within the 
Cardiovirus genus.  Experiments showing the importance of MDA-5 in sensing EMCV 
have lead to the investigation of MDA-5 in the sensing of other picornaviruses.  
However, in the previous chapter it was show that RIG-I also senses the infections with 
EMCV.  Therefore to investigate the role of RIG-I in sensing of picornaviruses for the 
Enterovirus genus, the human Coxsackievirus B3 (CVB3), which can also infect mice, 
was used to infect cells derived from RIG-I and MDA-5 knockout mice. 
 Infection of murine cells at a low MOI did not result in the induction of type I 
IFN, ISGs or cytopathic effect probably due to a different infectivity of CVB3 in murine 
cells than cells derived from its natural host, humans.  Therefore, infections of murine 
cells were done at high MOIs of 10-50.  At an MOI of 10 CVB3 infection of bone 
marrow derived macrophages elicited a Type I IFN response, but of a greatly reduced 
magnitude than that elicited by EMCV.  Similar to the infection of macrophages by 
EMCV the IFNβ response to CVB3 infection was very early in the mixed ICR 
background, peaking at 3 hours post infection and more gradual and delayed in a 
129x1/SvJ background not peaking until 12hours post infection (Figure 21A).  In the 
129x1/SvJ background CVB3 infection resulted in the induction of both IFNβ and IFNα 
in wild type macrophages which is lost when MDA-5 is knocked out.  In an ICR mixed 




reduced early in the absence of RIG-I early in infection, at the peak of IFNβ expression.  
Although IFNα was not induced in WT macrophages of a mixed ICR background, 
expression was induced in the absence of RIG-I (Figure 21 A and B).  A similar negative 
regulation of IFNα by RIG-I was seen previously in EMCV infected macrophages 
(Figure 18 B).  This difference between the induction IFNα message is also seen in IFNα 
protein levels (Figure 21C).  The effects of these observed differences in Type I IFN 
expression does not result in any differences in viral replication as CVB3 does not 
replicate in macrophages (Figure 21D).  Therefore, similar to EMCV, CVB3 infection of 
macrophages results in a non-productive infection that is sensed by MDA-5 to induce a 
IFNβ and IFNα response.  RIG-I contributes to positively to the induction of IFNβ but 




Figure 21. Role of MDA-5 and RIG-I in the induction of type I IFN in 
macrophages infected with CVB3. Bone marrow from knock out 
MDA-5 or RIG-I mice and their matched wild type controls were 
harvested and cultured in LCM conditioned media and infected with 
infected with CVB3 at an MOI=10. Total RNA was harvested at various 
times posit infection and expression of (A) IFNβ and (B) IFNα examined 
by qPCR.  (C) Supernatants were used to measure IFNα by ELISA. (D) 
Viral titers during infection were determined by plaque assay. 
Representative data from one experiment of three independent 
experiments.  Plaque assays performed in duplicate and qPCR 






RIG-I is essential for the production type I IFN during CVB3 infection of MEFs 
 CVB3 is able to replicate more robustly in MEFs than macrophages.  At an MOI 
of 1 the induction of IFNβ can be detected in wild type cells of the mixed ICR 
background, although magnitude of IFNβ induction is still notably lower than that of 
EMCV infection of these cells.  Increasing the MOI of infection results in an increase in 
induction of IFNβ although at a very high MOI of 50 this induction is not seen until 24 
hours post infection, similar to the induction of IFNα.  The increase of type I IFN after 
infection also results in the increase of ISGs shown by increases in ISG49 mRNA and 
ISG56 protein, and to a lesser extent OAS mRNA.  In the absence of RIG-I the increase 
in type I IFN, ISG49, ISG56 and the small increase in OAS are completely ablated, 
indicating that RIG-I is essential for the sensing of CVB3 infection and the induction of 
type I IFNs (Figure 22A-E).  However, it appears that the loss of Type I IFN induction 
does not correlate with a loss of an effective antiviral state since viral replication appears 
to decrease in the absence of RIG-I, indicating that the type I IFN response is not 








Figure 22.Role or RIG-I in the induction of an antiviral state in 
MEFs infected with CVB3. RIG-I deficient MEFs and their matched 
wild type controls were infected with CVB3 at an MOI of (A-B) 1, (C-D) 
10, (E-F) 50.  At various points post infection total RNA, virus and 
protein lysates were collected.  (A,C,E) RNA was used to measure gene 
expression for indicated genes by qPCR (B,D) Lysates were analyzed 
by western blot  for ISG56 and actin (control). (F) Virus titers were 
measured by plaque assay. Representative data from one experiment 
of three independent experiments.  Plaque assays performed in 
duplicate and qPCR performed in triplicate.  Error bars show standard 





MDA-5 has a type I IFN independent role in inhibiting CVB3 replication in MEFs 
 Infection of 129x1/SvJ MEFs with CVB3 at an MOI of 50 resulted in a very 
modest increase of IFNβ and IFNα peaking at 6 hours post infection.  In the absence of 
MDA-5 an increase in IFNβ and IFNα was still observed and peaked at 24 hours post 
infection indicating that MDA-5 is not essential for the induction of type I IFNs (Figure 
23B, C).  The increase in Type I IFN message did not however lead to an increase in 
expression of the ISG OAS in either the wild type or the MDA-5 deficient cells (Figure 
23D).  Interestingly, despite the absence of an antiviral state detectable by OAS induction 
and the absence of a notable difference in type I IFN production between wild type and 
MDA-5 deficient MEFs, there is a difference in the replication of CVB3 in the two cell 
lines.  CVB3 replicates to titers ten fold higher in the absence of MDA-5 (Figure 23A).  
This indicates that MDA-5, while not essential for the induction of type I IFN is 








Figure 23. Role of MDA-5 in the induction of an antiviral state in 
MEFs infected with CVB3. MDA-5 deficient MEFs and their matched 
wild type controls were infected with EMCV at an MOI=50.  At various 
times post infection total RNA and total virus was harvested. (A) Viral 
titers during infection were determined by plaque assay and (B) IFNβ 
(C) IFNa and (D) OAS expression determined by qPCR. Representative 
data from one experiment of three independent experiments.  Plaque 
assays performed in duplicate and qPCR performed in triplicate.  Error 





 Additionally, treatment of wild type and MDA-5 deficient MEFs with UV 
inactivated CVB3 showed that the modest amounts of type I IFN induced is dependent on 
viral replication. (Figure 24A, B)  However, in the absence of viral replication and of a 
type I IFN response a modest induction of the ISG OAS was detected, but only in MDA-
5 knockout MEFs.  (Figure 24C)  This may indicate the ability for MDA-5 to inhibit the 
sensing of non-replicating virus through a type I IFN independent manner.  UV exposure 
causes adjacent pyrimidines	  to	  form	  dimers	  through	  covalent	  bonds.	  	  This	  damage	  
prevents	  or	  stalls	  translations	  by	  ribosomes	  preventing	  the	  expression	  of	  viral	  
proteins	  and	  replication	  of	  genomes	  (167).	  	  Therefore	  the	  viral	  ligands	  being	  sensed	  





Figure 24. Role of CVB3 replication on the induction of an antiviral 
state in MDA-5 and matched wild type MEFs. Wild type and MDA-5 
deficient MEFs were treated with UV inactivated CVB3 at concentration 
of 50 UV inactivated pfu per cell, EMCV at an MOI=1 or mock treated. 
Total RNA was collected at 24hrs p.i. from mock (M) and EMCV (24C) 
treated cells as controls and at varying times post UV inactivated CVB3 
treatment and expression of (A) IFNβ (B) IFNa and (C) OAS determined 
by qPCR. Representative data from one experiment of two independent 
experiments, qPCR performed in triplicate.  Error bars show standard 





To ensure that the antiviral state produced by MDA-5 was independent of type I 
IFN, MEFs unable to respond to type I IFNs due to the knockout of the interferon alpha 
receptor 1 (IFNAR-/-) were obtained in a 129x1/SvJ background.  These MEFs were 
infected along with wild type and MDA-5-/- MEFs and viral titers measured at varying 
times post infection.  As seen previously CVB3 titers increased modestly in wild type 
MEFs.  In the absence of MDA-5 viral growth was about ten fold greater.  This was seen 
both at a high MOI of 50 where the level of some type I IFN induction could be detected 
as well as at a lower MOI of 1 where no type I IFN induction was detectable by qPCR.   
In the absence of IFNAR viral growth was slightly greater than it was in wild type MEFs, 
but not as great at in MDA-5-/- MEFs (Figure 25).  This further indicates that sensing 






Figure 25. Effect of MDA-5 and IFNAR on CVB3 replication. MDA-5-/- 
and IFNAR-/- MEFs were infected with CVB3 at (A) MOI=1 or (B) 
MOI=50.  At various times post infection samples were harvested for 
total virus and titer determined by plaque assay. Representative data 
from one experiment of two independent experiments.  Plaque assays 
performed in duplicate and qPCR performed in triplicate.  Error bars 





It was previously shown in our lab that the Cardiovirus EMCV is sensitive to type 
I IFN, being completely unable to replicate in cells pre-treated with IFNα.  The   
Enterovirus poliovirus however, was able to replicate in cells pre-treated with IFNα and 
described as an interferon resistant virus (101).  To determine if type I IFNs could have 
an effect on CVB3 replication, HeLa cells mock or pre-treated with IFNα at the very 
high dose of 1000 units/mL to establish an antiviral state cells were infected with CVB3.  
IFNα pre-treatment reduced the levels of CVB3 growth in HeLa cells similar to the 
reduction of poliovirus growth in IFNα pretreated cells indicating that CVB3 is an 
interferon resistant virus (Figure 26A).  The poliovirus 2A protease was shown to be 
responsible for the ability of poliovirus to evade type I IFN pre-treatment.  This ability 
was dependent on the presence of a tyrosine at residue 88 of 2Apro which is though to be 
involved in the discernment of protease substrates (101).  An alignment of the poliovirus 
and coxsackievirus 2A proteases shows the presence of a tyrosine at coxsackie residue 
which corresponds to the tyrosine at position 88 of poliovirus 2A, suggesting that the 
ability of CVB3 to replicate in the presence of type I IFN is similar to that of poliovirus: 
it is able to cleave some ISGs which are inhibitory to its replication.  However, CVB3 
must not be able to inhibit all inhibitory ISGs since some decrease in viral titer is 







Figure 26. Resistance of CVB3 growth to IFNa pretreatment. (A)  
HeLa cells were treated with or without 1000U/mL of IFNa for 16 hours 
and infected with CVB3 at an MOI=1.  At various points post infection 
total virus was harvested and titers determined by plaque assay. (B) 
Alignment of poliovirus and coxsackie B3 virus 2A proteases.  The 
asterisk marks the conserved tyrosine at amino acid 88. Representative 
data from one experiment of two independent experiments.  Plaque 





MDA-5 sensing of CVB3 infection of MEFs is independent of type III IFN 
 Type III IFNs have been shown to be under the control of the transcription factors 
NFκB, AP-1 and IRFs similar to type I IFNs (108).  Therefore type III IFNs are 
frequently induced in response to the same triggers that lead to type I IFN , however, 
differences in the expression of type I IFN and type III IFN have been noted.  
Macrophages infected with HSV have been shown to induce type I IFN but not type III 
IFN  and epithelial cells infected with influenza A produce higher levels of type III IFNs 
than type I IFN (160).  These differences are likely due to difference in the amount of 
dependence each IFN has for the various transcription factors.  Type I IFNs are strongly 
dependent on IRFs while type III IFNs have been found to be more dependent on NFκB 
(50, 150).  Additionally there are some differences in the signaling of type III IFNs from 
the signaling of type I IFNs since type I IFNs produce a positive feedback loop in which 
they up-regulate the expression of more type I and type III IFN.  Type III IFN signaling 
however does not result in an increase in type I or type III IFN expression (5).  We 
therefore hypothesized that type III IFNs would be a likely candidate for a type I IFN 
independent inhibition of CVB3.  Although no notable differences in induction of type I 
IFNs was found between wild type and MDA-5 deficient MEFs, the loss of MDA-5 may 
result in a loss of type III IFN expression.  Additionally, since type III IFNs use a 
different receptor for signaling they may preferentially activate a different assortment of 
STATs to induce a different array of ISGs than type I IFNs.  It could be possible that 
these ISGs would be once which CVB3 does not cleave to allow replication in IFNα 




 Therefore total RNA was collected from wild type, MDA-5 and IFNAR MEFs 
infected with CVB3 at an MOI of 1 and 50.  Induction of the type III IFNs IFNλ2 and 
IFNλ3 detected by the same primer set was examined by qPCR.  If type III IFNs were 
responsible for the antiviral effects of MDA-5 we expected the induction of IFNλ2/3 to 
be lower in MDA-5 deficient cells but instead found that IFNλ expression was not 
induced at all in wild type MEFs but was induced in the absence of MDA-5.  The 
induction of IFNλ2/3 in MDA-5-/- MEFs was even detectable in MEFs infected at the low 
MOI of 1, in which no induction of type I IFNs was found (Figure 27).  This therefore 
shows that inhibitory effect of MDA-5 on CVB3 replication is independent of type III 
IFN as well as type I IFN.  It also suggests that MDA-5 negatively regulates type III IFN 






Figure 27. Role if MDA-5 and IFNAR on type III IFN expression in 
MEFs infected with CVB3. Wild type, MDA-5 and IFNAR deficient 
MEFs were infected with CVB3 at (A) MOI=1 and (B) MOI=50.  Total 
RNA was harvested and qPCR for murine IFNλ2/3 performed. 
Representative data from one experiment of three independent 
experiments, qPCR performed in triplicate.  Error bars show standard 





 In summary, similar to EMCV, CVB3 replicated poorly in murine macrophages, 
but was able to be sensed.  MDA-5 was essential for this sensing and RIG-I contributed 
to the full expression of IFNβ but not IFNα, which RIG-I expression had a negative 
effect on.  In MEFs CVB3 was able to replicate, MDA-5 inhibited replication but did not 
contribute to type I IFN expression.  Meanwhile RIG-I enhanced viral replication but 
sensed infection to produce a type I IFN response.  The MDA-5 inhibition of CVB3 
replication was independent of type III IFN as well as type I IFN.  MDA-5 was also 





Chapter 5: Sensing of Poliovirus 
 
Poliovirus infection is sensed by MDA-5 
 Poliovirus is the best-studied and model picornavirus because it is the etiological 
agent of paralytic poliomyelitis – one of the most significant diseases caused by 
picornaviruses.  However, little has been done to examine the sensing of this 
picornavirus.  Two studies crossed transgenic mice expressing the human poliovirus 
receptor (PVR Tg) to mice lacking various sensors and shown that in vivo, TLR3 is 
important for the sensing of poliovirus in mice since there is a consistent increase in 
mortality, viral load and decrease in type I IFNs and ISGs in certain tissues after infection 
of PVR Tg/TRIF-/- mice (1, 110).  However in vivo infections of PVR Tg/MDA-5-/-, PVR 
Tg/RIG-I-/-, and PVR-Tg/IPS-/- mice do exhibit an increased mortality under various 
conditions.  The importance of these sensors in poliovirus infections may be obscured by 
the complexity of various cell types involved in in vivo experiments, especially during 
unnatural routes of infection such as intraperitoneal and intravenous injections that 
override natural immune barriers and provide immediate access to many tissues. 
 Therefore the sensing of poliovirus infection was studied in vitro using human 
HeLa cells knocked down for the sensor MDA-5 (Figure 12).  Infection of control and 
MDA-5 knockdown cells with poliovirus showed a great decrease in the induction of 
IFNβ in cells with reduced levels of MDA-5.  However, no change was seen in viral titers 
since the induction of IFNβ occurred late in infection, at 8-12 hours post infection and 







Figure 28. Role of MDA-5 on IFNβ  expression in HeLa cells infected 
with poliovirus. Control and MDA-5 knockdown cell lines were infected 
with poliovirus at an MOI of 0.01. (A) Total virus was collected at various 
times post infection and titer determined by plaque assay.  (B) RNA was 
harvested and expression of IFNβ determined by qPCR. Representative 
data from one experiment of two independent experiments.  Plaque 
assays performed in duplicate and qPCR performed in triplicate.  Error 





This is quite different from the response seen for EMCV infection of HeLa cells 
in which there was little change in IFNβ and ISG expression in the absence of MDA-5 
(Figure 15).  One of the differences between EMCV and poliovirus is the 2A viral 
protein, of which poliovirus 2A has protease activity and EMCV 2A does not (182).  The 
protease activity of poliovirus is important for cleavage of the viral polyprotein into 
mature viral proteins as well as the cleavage of various host proteins.  A mutation of a 
tyrosine at residue 88 of poliovirus 2A to a leucine changes the substrate binding loop in 
a manner which still allows for cis cleavage of the polyprotein but not trans cleavage of 
host proteins such as the translation factor eIF4G(175).  To determine if the 2A protease 
plays a role in the difference in dependence on MDA-5 for sensing of poliovirus and 
EMCV infections, control and MDA-5 knock down cell lines were infected with a 
poliovirus mutant containing the mutation of tyrosine at residue 88 of 2A to leucine (PV-
Y88L).  Similar to infections with poliovirus, the PV-Y88L mutant induced IFNβ, but 
after the peak of viral replication.  Therefore the expression of IFNβ had no effect on 
viral titers.  However, unlike infections with poliovirus the PV-Y88L mutant induced an 
IFNβ response in MDA-5 knockdown cell lines to levels greater than those in the control 
cell line (Figure 29), suggesting that the poliovirus 2A protease has a positive effect on 







Figure 29. Role of MDA-5 on IFNβ  expression in HeLa cells infected 
with PV-Y88L.  Control and MDA-5 knockdown cell lines were infected 
with the poliovirus mutant PV-Y88L at an MOI of 0.01. (A) Total virus 
was collected at various times post infection and titer determined by 
plaque assay.  (B) RNA was harvested and expression of IFNβ 
determined by qPCR. Representative data from one experiment of two 
independent experiments.  Plaque assays performed in duplicate and 






Previously our lab had shown that the 2A protease activity of poliovirus is 
necessary but not sufficient to allow for viral replication in IFNα pretreated cells.  
Absence of the protease activity in the PV-Y88L mutant prevented the replication of 
poliovirus in IFNα pretreated cells but addition of the 2A protease into EMCV, which is 
unable to replicate in IFNα pretreated cells only allowed the EMCV mutant (EP4) to 
replicate in cells pretreated with a low concentration of IFNα but was not sufficient to 
allow for EMCV replication in cells pretreated with high concentration of IFNα.  To see 
if the protease activity of poliovirus 2A is capable of inducing the ability for EMCV to be 
sensed by MDA-5, control and MDA-5 knockdown cells were infected with the EMCV 
mutant EP4 which contains the poliovirus 2A protease within the EMCV genome.  EP4 
was able to induce an IFNβ response in both control and MDA-5 knockdown cells with 
little difference in the amount of IFNβ induced, similar to EMCV (Figure 30 A, B). 
However a clone of EP4, EP4C4 (which was originally isolated based on its greater 
ability to replicate in cells pretreated with high amounts of IFNα) did show a greater 
dependence on MDA-5 for sensing indicated by a reduced amount of IFNβ produced in 
the absence of MDA-5 (Figure 30 C, D).  This indicates that additional changes were 
required for the EMCV to be sensed by MDA-5 in HeLa cells.  Sequencing of EP4C4 has 
shown 3 residue changes from EP4 in the L, 2B and 3C proteins.  Interestingly 3C is a 
viral protease that has been suggested to be involved in evasion of viral sensing for some 








Figure 30. Role of MDA-5 on IFNβ  expression in HeLa cells infected 
with EMCV mutants.  Control and MDA-5 knockdown cell lines were 
infected with (A-B) EP4 or (C-D) EP4C4.  (A, C) Total virus was 
collected at various times post infection and titer determined by plaque 
assay.  (B, D) RNA was harvested at various times post infection and 
expression of IFNβ determined by qPCR. Representative data from one 
experiment of two independent experiments.  Plaque assays performed 
in duplicate and qPCR performed in triplicate.  Error bars show standard 





 It is possible that poliovirus and EMCV can be sensed through multiple pathways 
but certain pathways are evaded by the ability of the viral proteases to cleave proteins 
involved in each signaling pathway.  The inhibition of sensing through one pathway then 
leads to sensing through another pathway, which in some cases may be more or less 
robust in activating IFNβ transcription.  To investigate alternate sensing pathways a 
HeLa cells were knocked down for RIG-I, the other cytoplasmic RNA sensor, and IPS-1 
down stream adaptor molecule for both RIG-I and MDA-5.  The RIG-I knockdown 
would allow for determination of the role of sensing through an alternate cytoplasmic 
receptor pathway and the knockdown of IPS would allow for the determination of the 
role of non-cytoplasmic receptor sensing, i.e. TLR sensing.  The knock down of RIG-I 
resulted in non-detectable basal levels of RIG-I by western blot.  The induction of RIG-I 
expression by IFNα or pI:C treatment however increased levels of RIG-I in the RIG-I 
knockdown cell line to levels which are detectable by western blot.  These levels 
however were greatly reduced in comparison to those in IFNα and pI:C treated control 
knockdown cells (Figure 31A).  Two variants of IPS-1 are produced in human cells 
giving rise to proteins detected at 80kDa and 60kDa.  The IPS-1 knockdown cell line 
reduced the level of both these forms to undetectable levels by western blot analysis 
(Figure 31B).  These cell lines will be used in future studies to investigate the ability for 







Figure 31. Knockdown of RIG-I and IPS-1 in HeLa cells.  (A) Control 
or RIG-I knockdown HeLa cell lines were mock treated or treated with 
1000U/mL of IFNa or 20ug/mL of pI:C for 16hrs and cell extracts were 
analyzed by western blot for RIG-I.  (B) Extracts of control and IPS-1 
knockdown HeLa cell lines were analyzed by western blot for IPS-1.  
Arrows indicate 80KDa and 60KDa forms of IPS-1. Representative data 





Because poliovirus is a cytopathic virus and IFNβ responses were induced late in 
infection, after the peak of viral replication when cells appeared to be in late stages of 
apoptosis, the contributions of apoptosis to IFNβ induction was tested by the induction of 
apoptosis by staurosporine treatment.  Staurosporine is a kinase inhibitor which induces 
apoptosis.  Western blot analysis for poly ADP ribose polymerase (PARP), a substrate of 
caspases was performed on lysates at various times post treatment to ensure the 
occurrence of apoptosis and qPCR done to determine the induction of IFNβ.  Caspase 
activation was confirmed but no amplification of IFNβ was seen by qPCR although 
amplification of the standard curve and the internal control, GAPDH, were observed 
(Data not shown).  Additionally the activation of caspases, the executioners of apoptosis, 
were inhibited during poliovirus infections using the pan-caspase inhibitor QVD.  In cells 
treated with the solvent DMSO caspase activation, indicated by PARP cleavage was 
detected at 9 hours after infection, while no cleavage was detected in QVD treated cells 
(Figure 32A and B).  The inhibition of caspase activation however had no effect on viral 
growth and minimal effect on IFNβ expression (Figure 32 C and D).  This indicates that 








Figure 32.  Effect of apoptosis on poliovirus induced IFNβ  
expression. HeLa cells were mock treated with QVD or DMSO solvent 
as a control and infected with poliovirus at an MOI=1.  At various times 
post infection (A-B) protein lysates (C) total virus and (D) RNA were 
collected. Apoptosis during infection in the presence of (A) DMSO and 
(B) QVD was detected by western blot analysis for PARP cleavage. (C) 
Total virus titers were determined by plaque assay. (D) Expression of 
IFNb was determined by qPCR. Representative data from one 
experiment of two independent experiments.  Plaque assays performed 
in duplicate and qPCR performed in triplicate.  Error bars show standard 






Chapter 6: Discussion 
 
 The cytoplasmic receptors RIG-I and MDA-5 were initially thought to sense 
distinct sets of viruses.  It has been commonly cited that RIG-I recognizes infections by 
most families of RNA viruses while MDA-5 senses viruses of the Picornaviridae family 
(2, 71, 118, 147, 165). This distinction was made from a set of experiments infecting 
MEFs, BMDCs and mice with an array of different RNA viruses and looking for crude 
differences in type I IFN expression and animal survival as indications of sensing.  While 
theses initial studies were very informative, more recent work has begun to elaborate on 
the generalized conclusions made from them.  One conclusion made was that RIG-I was 
the sensor for flaviviruses based on experiments using Japanese Encephalitis virus (59).  
Although the flaviviruses Japanese Encephalitis virus, Hepatitis C virus, West Nile virus 
and Dengue virus are all sensed by RIG-I, Dengue virus and West Nile virus have also 
been shown to be sensed by MDA-5.  It was therefore concluded that genomes of these 
viruses contained structures that were ligands for both MDA-5 and RIG-I .  We therefore 
were interested in further developing the understanding of sensing using viruses of the 
picornavirus family and found that the discernment between sensors is dependent on 
more than just structural features of the viral genome. 
  
RIG-I senses picornaviruses 
 It is already well known that picornaviruses are sensed by MDA-5 but few studies 
have looked at the sensing of picornaviruses by RIG-I.  It has been suggested that sensing 




phosphates as well as the ability for picornaviruses to evade RIG-I signaling through the 
viral 3C protease.  The 3C protease of Enterovirus 71 has been shown to inhibit IFNβ 
promoter activity stimulated by Sendai virus or constitutively active RIG-I, independent 
of its protease function .  Poliovirus, echovirus, rhinovirus 16 and EMCV however have 
been shown to cleave RIG-I during infection using the 3C protease .  In MDA-5 deficient 
MEFs the IFNβ promoter is not activated upon EMCV infection, however activity can be 
detected in infection if RIG-I is over expressed, showing that RIG-I is capable of sensing 
EMCV infection. 
Through our use of RIG-I knock out MEFs and macrophages we have shown that 
not only can RIG-I sense picornavirus infections but also that RIG-I does sense 
picornavirus infection.  CVB3 infection of macrophages deficient in RIG-I resulted in a 
decreased level of IFNβ expression while infection of RIG-I deficient MEFs resulted in a 
complete loss of IFNβ expression.  Therefore, for CVB3 RIG-I is necessary for the 
maximal induction of IFNβ in macrophages and is essential for the production of type I 
IFNs in MEFs (Figure 21 and 22).  EMCV infections of RIG-I deficient macrophages and 
MEFs resulted in decreased levels of IFNβ expression, and in MEFs a decrease in IFNα 
expression as well.  This indicates that during EMCV infections RIG-I is necessary for 
the maximal production of IFNβ in macrophages and IFNβ and IFNα in MEFs (Figure 
18 and 19).   
No previous studies had been done to examine the role of RIG-I in CVB3 
infection but for EMCV it has been shown that the absence of RIG-I does not produce a 
significant effect on Type I IFN expression in MEFs and BMDC .  The differences in our 




examined since our studies used BMDM as opposed to BMDC.  Additionally our studies 
in leukocytes showed differences the induction of type I IFNs occurred early after 
infection peaking at three to six hours post infection in RIG-I-/- and matched wild type 
control cells (Figure 18 and 21) while other studies only looked at one time point at 24 
hours after infection.  At this point we found that Type I IFN expression was low and 
levels between RIG-I-/- and wild type cells were comparable.   
The differences between published data and our data in MEFs, where we found 
IFN induction to be late with peak expression at 24 hours after infection, are likely due to 
background differences.  Our RIG-I-/- MEFs were derived from viable mice obtained by 
the crossing of heterozygous RIG-I mice in a mixed 129x1/SvJ and C57BL/6 background 
with outbred ICR mice.  While other studies used MEFs in a 129Sv X C57BL/6 
background in which both RIG-I-/- and MDA-5-/- mice were lethal at embryonic day 12.5 
.  Although this background allows for the direct comparison of the roles of MDA-5 and 
RIG-I in infection it cannot be assumed that their roles would be as clearly defined in a 
viable mouse. 
This new finding of RIG-I contributing to picornavirus sensing leads to the 
conclusion that picornavirus infections produce an RNA ligand recognizable by RIG-I.  
Because the ends of RNA molecules recognized by RIG are thought to be important and 
the ends of picornavirus genomes are obstructed due to the requirement of a protein 
primer, VPg, to initiate viral RNA polymerization how RIG-I senses picornavirus RNA is 
an interesting question (Figure 4).  One possible explanation is that RIG-I is sensing the 
viral RNAs that do not have VPg attached.  It has been shown that once viral RNA has 




monophosphate end (4, 44, 104).  This unlinked RNA with an unobstructed 5’ end may 
now be recognized by RIG-I, or more likely the unlinked RNA bound to a negative sense 
strand of viral RNA (RF RNA) since it has been shown that RIG-I can recognize double 
stranded RNA with one strand monophosphorylated(145).  To investigate this isolated RF 
RNA could be transfected into cells and sensing measured.  Additionally localization 
studies should indicate the presence of RIG-I at replication complexes where RF RNA is 
found. 
Because the levels of RF RNA with in a cell are low it is also possible that RIG-I 
is sensing a more abundant RNA structure such as the IRES.  These highly structured 
RNA domains contain many double stranded regions which may be ligands for RIG-I 
since RIG-I can also bind double stranded RNA.  To investigate this gel shift assays can 
be performed with RIG-I and IRES structures to show binding.   
 
Coxsackievirus B3 replication is inhibited by an IFN independent mechanism 
 The absence of MDA-5 or RIG-I in macrophages infected with EMCV or CVB3 
results in decreased antiviral state but does not result in an increase in viral growth since 
both EMCV and CVB3 replicate poorly in macrophages (Figure 18 and 21).  
Both viruses do however replicate well in MEFs, but the absence of RIG-I or MDA-5 in 
MEFs still has no effect on viral growth of EMCV even though it has an effect on the 
expression of type I IFNs and ISGs since the induction of theses genes does not occur 
until after the peak of total viral replication (Figure 19).  
The absence of RIG-I during CVB3 infection however appeared to inhibit the 




such as ISG 49, ISG 56 and OAS.  Interestingly this did not result in an increase in viral 
replication compared to replication in wild type cells but in a decrease in viral replication 
(Figure 22 and 33).  The absence of MDA-5 during CVB3 infection showed no 
appreciable difference in the induction of type I IFNs, which was low enough to not 
result in an increase in the expression of the ISG OAS.  However, MDA-5 deficiency did 
result in an increase in viral titers (Figure 23 and 33).  This inhibitory effect of MDA-5 
on CVB3 replication was apparent not only at the high MOI of 50 which was needed to 
see an induction of type I IFN, but also at a lower MOI of 1 at which no increase in type I 
IFNs could be detected (Figure 24).  The increase in viral titer in the absence of MDA-5 
despite the lack of decrease in type I IFN, along with the decrease in viral titers in the 
absence of RIG-I which does result in a decrease in type I IFN, indicates that there must 
be factors independent of type I IFN expression that are inhibiting CVB3 replication.  
This supports in vivo work where infections of MDA-5-/- mice show no significant 
increase in IFNα serum levels or IFNβ or OAS expression in tissues, yet a transient early 
increase in CVB3 titers, which lead to increased tissue damage and disease is observed 
(48).  Infection of IFNAR-/- MEFs confirmed this type I IFN independent inhibition of 
CVB3 replication since viral titers in these cells were lower than those in MDA-5 MEFs 
at both an MOI of 1 and an MOI of 50 (Figure 24).  Titers in IFNAR-/- MEFs were 
slightly higher than those of wild type MEFs indicating that type I IFN does have a slight 
role in inhibiting CVB3 replication but is not fully responsible for the MDA-5 dependent 
inhibition of CVB3 replication.  Additionally CVB3 was found to be able to replicate in 
the presence of an antiviral state induced by type I IFN, further supporting the idea that 




Type III IFNs have been found to also be induced in response to viral infections 
and to be capable of producing an antiviral state after signaling through their receptors.  
Quantitative PCR for IFNλ2/3 expression also did not show a decreased induction in the 
absence of MDA-5.  Interferon λ2/3 expression was instead induced in the absence of 
MDA-5.  The kinetics of this induction was late, similar to that of type I IFNs, beginning 
at nine hours post infection, and therefore likely to not have a causative role in the 
increase in viral replication in MDA-5 deficient MEFs, which begins earlier in infection 










Figure 33.  Coxsackievirus infection of MEFs. An infecting virus 
replicates its genome by first producing a complementary negative 
strand of RNA followed by multiple positive sense strands of RNA off of 
the negative strand. New genomic RNAs are used to form new 
infectious particles.  The sensors MDA-5 and RIG-I bind some form of 
viral RNA as the virus replicates.  Binding of RNA to RIG-I results in the 
expression of type I IFNs and ISGs, but not the inhibition of viral 
replication.  The presence of RIG-I actually results in an increase in viral 
replication.  Binding of RNA to MDA-5 does not result in the expression 
of type I IFNs but results in a decrease in viral replication and the 






It is known that viral sensing results in the induction of many cytokines under the 
control of NFκB in addition to IFNs.  One of these other cytokines may be contributing 
to decreases in CVB3 replication. 
 However a more appealing explanation is that MDA-5 is signaling through IPS-1 
on the peroxisome.  It has been found that an IFN independent antiviral state may be 
induced by RIG-I through signaling using peroxisomal IPS-1 rather than mitochondrial 
IPS-1 (21).  This signaling was found to induce expression of ISGs directly through the 
activation of IRF1 and to do so before the induction of type I IFNs.  If MDA-5 can also 
signal through peroxisomal IPS it could inducing an effective early antiviral response that 
results in a decrease in CVB3 titers.  Since differences in viral titers are seen early in 
infection, this seems like a plausible explanation.  The expression of ISGs under control 
of the IRF1 transcription factor can be examined to determine this.  It would also be 
expected that these ISGs would be the ones which are responsible for the slight decrease 
in CVB3 replication in HeLa cells pretreated with IFNα.  Therefore if IRF1 dependent 
ISGs are up-regulated in wildtype but not MDA-5-/- MEFs over expression of these ISGs 
should be able to reduce viral replication. 
 If RIG-I signaling in this context olny occurs through mitochondrial IPS-1 this 
could also explain why the induction of type I IFNs and ISGs by RIG-I does not limit 
viral replication but promotes it.  The inability for type I IFN signaling to have an effect 
on viral replication is due to the lateness in the response after viral replication is 
complete.  Additionally the sensing of viral RNA by RIG-I may compete with the ability 
for MDA-5 to bind and sense viral RNA.  Therefore in the presence of RIG-I the early, 




greater than in the absence of RIG-I.  Immunofluorescence staining of RIG-I, 
mitochondrial and peroxisomal markers after infection would verify this hypothesis.  
 
Involvement of RIG-I and MDA-5 in sensing varies based on host, cell type, and genetic 
background 
 Although RIG-I was not essential for the sensing of EMCV in either macrophages 
or MEFs, MDA-5 was found to be essential for the production of type I IFNs in 
macrophages but not in MEFs where there was still an induction of IFNβ and IFNα 
message, albeit greatly reduced (Figure 18 and 19).  MDA-5 was also found to be 
essential in the induction of IFNβ and IFNα expression in response to CVB3 infection in 
macrophages. However, in MDA-5-/- MEFs type I IFNs were produced to levels equal to 
or greater than those in wild type MEFs (Figure 21 and 23).  The role of RIG-I in CVB3 
infection also varied depending on the cell type infected, where it was essential for the 
sensing of CVB3 in MEFs but only contributed to the induction of maximal levels of 
IFNβ in macrophages (Figure 21 and 22).  These differences highlight the importance of 
cell type in sensing since the involvement of RIG-I and MDA-5 changes for the same 







Table 5.  Summary of data from EMCV and Coxsackievirus 
infections.  Results from infections of cell lines deficient in indicated 
genes by indicated viruses is described in respect to the effect in control 
cells.  (+) values greater than control (-) values less than control (--) 
values less than control to the extent of an absent response (±) values 






In addition to the cell types resulting in differences in sensing through different 
RLRs, different cell types also contribute to differences in viral growth, which may 
contribute to the differences in sensing.  For both EMCV and CVB3 viral replication in 
macrophages was poor while in MEFs both viruses were able to grow (Figures 18, 19, 21, 
22 and 23).  This defect is not due to the early type I IFN antiviral response observed 
after infection since the absence of MDA-5 results in the loss of this response but not an 
increase in replication.  This defect may be to the expression more proteins with intrinsic 
immune functions in macrophages, protecting them from active viral infections by many 
viruses (96-98, 166).  One such protein is SAMHD1 which was recently found to restrict 
the infection of dendritic and other myeloid cells from HIV by keeping the level of 
intracellular dNTPs too low for the polymerization of viral DNA in the cytoplasm (73) 
(Table 5). 
 We were not able to compare the roles of MDA-5 or RIG-I within different strain 
backgrounds to determine the role of murine strain on sensor usage, although we did 
notice differences between the induction of type I IFNs in wild type macrophages of 
different backgrounds.  Macrophages in a mixed ICR background induced a robust type I 
IFN response early after infection with levels peaking at 3-6 hours post infection when 
infected with EMCV or CVB3.  Meanwhile infections of macrophages in a 129x1/SvJ 
background produced a more gradual and delayed induction of type I IFNs which peaked 
at six hour after infections with EMCV and 12 to 14 hours after infection with CVB3 
(Figure 18 and 21).  One possible explanation for this difference is different basal levels 
of sensors within macrophages of different backgrounds.  Quantitative PCR was used to 




found that although the ratio of RIG-I copes to MDA-5 copies in each background were 
similar, the basal levels of both RIG-I and MDA-5 are twice as high in macrophages in a 
mixed ICR background than those in a 129x1/SvJ background.  Also, the deletion of one 
sensor had no effect on the expression of the other sensor (Figure 17).  This may also 
explain why the role of RIG-I in vivo was not detected since the mixed ICR strain may be 
able to use an alternate sensing pathway more easily than other strains leading to a 
resistant strain in general, masking the effects of any sensor.  It has been previously 
shown that strain background can mask the effect of sensors using CVB3 where 
intraperitoneal infections of C57BL/6 mice with and without MDA-5 resulted in a much 
greater lethality in the MDA-5 deficient mice.  However intraperitoneal infections of wild 
type and MDA-5 deficient mice with the sane amount of virus in a 129x1/SvJ 
background showed no difference as both mice were completely resistant to infection 
(48). 
  With differences in cell type and strain background it is not surprising that 
differences in host organism also affects the role of sensing which is seen in the 
difference in EMCV infection of HeLa cells and murine cells.  In HeLa cells MDA-5 
appears to not be important in infection as levels of IFNβ in MDA-5 knockdown cells are 
limited and differences in levels of ISGs are inappreciable (Figure 16).  However, in 
MEFs MDA-5 deficiency results in a striking decrease in type I IFN and ISG production 
and in macrophages is essential in triggering a type I IFN response and ISG induction 
(Figure 18 and 19).  Taken together this all shows that the discernment between sensor 





Sensors can positively and negatively regulate antiviral responses  
 The sensing of viral infections is key to initiating an immune response to limit and 
clear an infection.  Type I IFNs have been known to play a key role in this since their 
signaling leads to the induction of hundreds of ISGs, which create an intracellular 
antiviral state to limit viral replication but also aid in extracellular defenses against viral 
infection through the expression of chemokines which aid in the recruitment of 
leukocytes.  Therefore the induction of type I IFNs is a standard readout for the sensing 
of viral infections.  The expression of these IFNs often correlates well with an increase in 
ISGs, a decrease in viral titers and a decrease in disease (Figure 34).  Therefore the 
absence of a sensor is assumed to result in a decrease in IFNs and ISGs and an increase in 






Figure 34.  Expected responses to viral sensing. An infecting virus 
replicates its genome by first producing a complementary negative 
strand of RNA followed by multiple positive sense strands of RNA off of 
the negative strand. New genomic RNAs are used to form new 
infectious particles.  A sensor recognizes some form of viral RNA to 
initiate a signaling cascade that results in the expression of cytokines 
including Type I and type III IFNs.  Interferon signaling results in the 
expression of ISGs.  Proteins encoded by ISGs function in 





This however, is not always the case.  For example, in the absence of RIG-I IFNβ 
expression after infection with EMCV and CVB3 is reduced, indicating that RIG-I is a 
sensor.  However the expression of IFNα, another type I IFN does not decrease in the 
absence of RIG-I but increases, indicating that RIG-I does not contribute to a protective 
immune response.  Since EMCV and CVB3 do not grow in macrophages changes in viral 
growth are not a good indicator of which type I IFN response, the decreased IFNβ 
response or increased IFNα response, is more indicative of viral sensing (Figure 18 and 
21).  Infections of MEFs deficient in RIG-I with CVB3 show a clear absence of IFNβ, 
IFNα and ISG expression indicating that RIG-I is sensing CVB3 infections in MEFs to 
induce an antiviral state.  However, this antiviral state is ineffective since it was found 
that titers of CVB3 actually decrease in the absence of RIG-I (Figure 22).  Additionally 
the growth of CVB3 in the absence of MDA-5 is reduced indicating that MDA-5 is 
involved in the triggering of an antiviral state.  However type I IFNs are not reduced in 
the absence f MDA-5 and type III IFNs expression is actually increased (Figure 23 and 
27).   
These data exemplify the complexity of inducing an antiviral response, even in 
vitro.  A sensor may positively regulate one antiviral response but negatively regulate 
another. 
 
Viral 2A protease has a role in “modulating” sensing 
In HeLa cells MDA-5 was found to be dispensable for the induction of IFNβ, 
IFNα and ISGs during infections with EMCV (Figure 16).  The knockdown of MDA-5 




(Figure 28).  Although EMCV and poliovirus are similar enough to belong to the same 
family they are different enough to belong to separate genera.  Differences in both the 
proteins and RNA genomes of the Cardiovirius and Enterovirus genera exist which could 
account for this difference in sensing.  The 5’ untranslated region of cardioviruses contain 
pseudoknots and a poly C tract which is absent in enteroviruses while enteroviruses have 
a 5’ clover leaf structure which is replaced by a simple stem loop in cardioviruses.  
Additionally the highly structured IRES region of picornavirus genomes which allows for 
cap-independent translation differs between the viruses (Figure 1).  These different RNA 
structures could act as different ligands for different sensors, however since MDA-5 is 
able to sense infections of EMCV in murine cells, and human and murine MDA-5 are 
80% identical, it is unlikely that this difference in structural features of the viral genome 
explain why EMCV is not sensed by MDA-5 in HeLa cells. 
Key differences in EMCV and poliovirus are the presence of an extra non-
structural leader protein, L, encoded in the EMCV genome which poliovirus lacks and 
the absence of protease activity in the EMCV 2A protein which is present in poliovirus 
2A.  Using a poliovirus mutant, PV-Y88L, which contains a mutation in the 2A protease 
to allow it to cleave the viral poly protein but not host cell proteins the ability for 2A to 
control sensing by MDA-5 in a protease dependent manner was tested.  The absence of 
the ability for the 2A protease to cleave host factors resulted in the ability for PV-Y88L 





Figure 35.  Sensing in HeLa cells.  (A) Poliovirus infections are 
capable of being sensed by more than one sensor but sensing through 
proteins other than MDA-5 are inhibited by the protease function of 2A.  
(B) EMCV infection is sensed by multiple sensors.  Addition of the 
poliovirus 2A protease and mutation of the L, 2B and 3C protein inhibits 
the ability for EMCV to be sensed by sensors other than MDA-5.  Only 
one or multiple of these changes may be needed to inhibit sensing 
through alternate paths.  Alternate paths of sensing could be through 






One explanation for this is that protease activity of 2A is involved in inhibiting an 
alternate sensing pathway such as sensing through RIG-I or TLR3 (Figure 35).  The 
expression of the poliovirus 2A protease during infections with EMCV should be able to 
inhibit the sensing of EMCV through these alternate pathways, resulting a dependence on 
MDA-5 for the sensing of EMCV.  The infection of control and MDA-5 knockdown cell 
lines with EP4, a mutant EMCV virus carrying the poliovirus 2A protease did not show a 
strong dependence on MDA-5 for sensing.  However a plaque purified clone of EP4, 
EP4C4, was more dependent on MDA-5 for sensing (Figure 30).  The recent sequencing 
of this clone has shown additional mutations in the L, 2B and 3C proteins.  EMCV 
mutants containing these individual mutations need to be made to determine which of 
these proteins in EMCV contributes to changing the dependence on MDA-5 for sensing.  
However changes in the 3C protein are interesting since it has been shown that the 3C 
protein is capable of inhibiting the RIG-I and TLR sensing pathway.  Hepatitis A and 
CVB3 3C proteases have been found to cleave TRIF and inhibit signaling (102, 124).  
EMCV 3C protease has been shown to be able to dampen RIG-I induced activation of the 
IFNβ promoter through by cleavage of RIG-I (114) and enterovirus 71 3C has been 
shown to bind RIG-I and inhibit its ability to activate the IFNβ promoter in a protease 
independent manner (77).  This mutation in 3C may confer or enhance the ability for 
EMCV to inhibit signaling through these pathways, leading EP4C4’s dependence on 
MDA-5 for IFNβ induction (Figure 35).  To investigate this idea we would like to 
examine the contribution of other sensing pathways to the sensing of poliovirus, PV-
Y88L, EMCV and EP4C4.  The creation of RIG-I and IPS-1 knockdown HeLa cell lines 




sensing.  We would hope to see sensing not occurring through RIG-I or any alternative 
pathway in infections with PV or EP4C4, but sensing through an alternative pathway in 
infections with PV-Y88L and EMCV. 
Alternatively it has been shown that other 2Apro mutations at tyrosine 88 have 
effects on viral RNA replication (157).  Therefore another possible cause for the change 
in dependence on MDA-5 for sensing may be due to a change in RNA replication, either 
a decrease in total viral RNA or a specific intracellular form of viral RNA (Figure 4) 
could also be factors affecting the ability of virus to be sensed by an alternate pathway.  
A correlation between kinetics of viral growth and sensing has not been observed (Figure 
28, 29 and 30) but the amount of infectious virus produced is not necessarily indicative of 
the amount of RNA produced.  Therefore further investigations should be done to 
examine the levels of viral RNA during infections through qPCR or northern blot 
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